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Avian Paramyxovirus (APMV) serotype 2 is one of the nine serotypes of 
APMV that infect a variety of bird species around the world. In chickens and turkeys, 
APMV-2 causes respiratory illness and drop in egg production. To understand the 
molecular characteristics of APMV-2, the complete genome sequences of prototype 
strain Yucaipa and strains Bangor, England and Kenya were determined. The genome 
lengths of APMV-2 strains Yucaipa, Bangor, England and Kenya are 14904, 15024, 
14904, 14916 nucleotides (nt), respectively. Each genome consists of six non-




 similar to most of 
APMVs. Sequence comparison of APMV-2 strains England and Kenya with 
prototype strain Yucaipa show 94–98% nt and 90–100% aggregate amino acid (aa) 
identities.  However, strain Bangor shares low level of nt and predicted aa sequence 
identities with the other three strains. The phylogenetic and serological analyses of all 
four strains indicated the existence of two subgroups: strains Yucaipa, England and 
Kenya represented one subgroup and strain Bangor represented the other subgroup. 
  
All four strains were found to be avirulent for chickens by mean death time and 
intracerebral pathogenicity test. 
To further study the molecular biology and pathogenicity of APMV-2, a 
reverse genetics system for strain Yucaipa was established in which infectious 
recombinant APMV-2 was recovered from a cloned APMV-2 antigenomic cDNA. 
The recovered recombinant virus showed in vitro growth characteristics and in vivo 
pathogenicity similar to wild type virus. Recombinant APMV-2 expressing enhanced 
green fluorescent protein was also recovered, suggesting its potential use as a vaccine 
vector. Furthermore, generation and characterization of mutant viruses by replacing 
the fusion protein (F) cleavage site of APMV-2 with those of APMV serotypes 1 to 9 
demonstrated that the amino acid composition at F protein cleavage site does not 
affect the pathogenicity of APMV-2. Overall, the study conducted here has several 
downstream applications. The complete genome sequence of APMV-2 is useful in 
designing diagnostic reagents and in epidemiological studies. The reverse genetics 
system for APMV-2 would be of considerable utility for introducing defined 
mutations into the genome of this virus and develop vaccine vector for animal and 
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Avian Paramyxovirus serotype 2 (APMV-2) belongs to the genus Avulavirus within the 
subfamily Paramyxovirinae in the family Paramyxoviridae. This virus family is large and 
diverse whose members have been isolated from many species of avian, terrestrial, and aquatic 
animals around the world (Lamb and Parks, 2007; Wang and Eaton, 2001). Paramyxoviruses are 
pleomorphic, enveloped and have a non-segmented, negative-sense RNA genome. During 
influenza virus surveillance programs, avian paramyxoviruses were also isolated and were 
classified into nine serotypes based on hemagglutination inhibition (HI) and neuraminidase 
inhibition (NI) tests (Alexander, 2003). The cross-HI and –NI tests suggested organizing APMV 
isolates into two broad subgroups; the first subgroup consisting of APMV-2 and -6 and the 
second subgroup consisting of APMV-1, -3, -4, -7, -8 and -9, while not much was known about 
APMV-5 (Lipkind and Shihmanter, 1986). Among them, Newcastle disease virus (NDV) 
belonging to APMV-1, is an economically important poultry pathogen and hence, the most well 
characterized virus within this genus. In contrast, little is known about the pathogenesis of other 
avian paramyxoviruses.  
APMV-2 is associated with mild respiratory illness in chickens and turkeys that gets 
exaggerated with secondary bacterial infections (Alexander, 1980). The virus was first isolated in 




strains have been isolated from chickens, turkeys and feral birds across the globe (Alexander et 
al., 1982; Asahara et al., 1973; Collings et al., 1975; Fleury and Alexander, 1979; Goodman and 
Hanson, 1988; Lang et al., 1975; Lipkind et al., 1979, 1982; Mbugua and Karstad, 1985; 
Nymadawa et al., 1977; Shihmanter et al., 1997; Weisman et al., 1984; Zhang et al., 2006, 
2007). Serological survey of chickens and turkeys has shown a wide prevalence of APMV-2 in 
the United States. APMV-2 is more prevalent in turkeys than chickens (Bankowski et al., 1968) 
and affects hatchability and poult yield (Bankowski et al., 1981). Surveillance of wild birds has 
indicated that APMV-2 is more frequently seen in passerines (Alexander, 1986; Senne et al., 
1983).  
The genome of APMV-2 has six genes arranged in tandem in the order of 3‟ -N-P-M-F-HN-
L- 5‟. There are conserved sequences present at the beginning and end of each gene, known as 
gene start (GS) and gene end (GE), respectively. The GS is recognized as a transcription 
initiation signal and the GE is recognized as a transcription termination signal by the viral RNA 
polymerase. Between each gene, non coding sequences of variable length called intergenic 
sequences (IGS) are present, which are shown to regulate the transcription efficiency of 
downstream genes in NDV (Yan and Samal, 2008). In addition, the genome of APMV-2 
contains a 55 nt long viral promoter known as leader at its 3‟ end and a 154 nt long viral 
antigenome promoter known as trailer at its 5‟ end (Subbiah et al., 2008). The leader and trailer 
regions serve as cis-acting elements in viral genome for replication and packaging of viral RNA 
(Lamb and Kolakofsky, 1996). APMV-2 genome encodes internal proteins: major nucleocapsid 
protein (N), a phosphoprotein (P) and a large polymerase protein (L); surface glycoproteins: 
fusion protein (F) and hemagglutinin-neuraminidase (HN) protein and a matrix protein M. Most 




within the P gene called RNA editing site directs non-templated addition of one or more G 
nucleotides to P transcripts by viral polymerase stuttering. This yields mRNA subpopulations 
with frame shifts causing alternate internal ORFs. Two non-structural proteins, V and W, are 
produced by one and two G insertions, respectively. The V protein has a highly conserved 
cysteine motif and has interferon antagonist activity in NDV (Huang et al., 2003).  
The outer surface glycoproteins, F and HN, mediate viral penetration and attachment, 
respectively. The F protein is synthesized as an inactive precursor (F0) which is cleaved at F 
protein cleavage site by host-cell proteolytic enzyme(s) into biologically active F1 and F2 
subunits connected by a disulphide bond (Scheid and Choppin, 1974). The avirulent NDV strains 
have a monobasic amino acid residue at the F protein cleavage site and a leucine at the F1 N 
terminus, while virulent NDV strains have multiple basic amino acids at the F protein cleavage 
site and a phenylalanine at the F1 N terminus (Nagai
 
et al., 1976; Ogasawara et al., 1992). Many 
studies have shown that the F protein cleavage site determines virulence of NDV. Accordingly, 
the World Organization of Animal Health considers the presence of multiple basic amino acids 
and phenylalanine at the F protein cleavage site as one of the important criteria to categorize 
NDV strains under virulent pathotype (OIE, Chapter 2.1.15).  The F protein cleavage site of 
APMV-2 has two basic amino acids and a phenylalanine at F1 N terminus and is avirulent in 
chickens (Subbiah et al., 2008). Furthermore, each APMV serotype has a unique F protein 
cleavage site and does not abide to the general rule seen with NDV strains. Hence in this study, F 
protein cleavage site mutants (each representing a particular APMV serotype) were generated in 
APMV-2 backbone using reverse genetics to understand the role of amino acid composition at 





Pathogenesis and molecular characteristics of APMV-2 have rarely been studied; only 
limited sequences of F and HN genes of APMV-2 (GenBank AF422844) and a partial L gene 
sequence, 2042 bp (GenBank AF515835) were previously accessible in GenBank. The complete 
genome sequences of none of the strains of APMV-2 were available. Therefore, in this study, the 
complete genome sequences of four strains of APMV-2 were determined and compared with 
those of other paramyxoviruses to understand the viral biology at molecular level. The 
knowledge of complete genome sequence is essential for genetic manipulation of the virus. The 
most successful system for genetic manipulation of negative-sense RNA viruses is a plasmid 
based system called reverse genetics. In this approach, four plasmids – one encoding the viral 
anti-genome and the others encoding the viral polymerase complex (N, P and L proteins), all 
under the control of T7 promoter are cotransfected in permissive cells expressing T7 RNA 
polymerase or in cells infected with recombinant vaccinia virus expressing T7 RNA polymerase. 
Many negative-sense RNA viruses have been recovered using this system (rabies virus, Schnell 
et al., 1994; vesicular stomatitis virus, Lawson et al., 1995; human respiratory syncytial virus, 
Collins et al., 1995; measles virus, Radecke et al., 1995; Sendai virus, Garcin et al., 1995; SV5, 
He et al., 1997; rinderpest virus, Baron and Barrett, 1997; parainfluenza virus, Hoffman and 
Banerjee, 1997; bovine respiratory syncytial virus, Buchholz et al., 1999 and Yunus et al., 2001; 
Newcastle disease virus, Peeters et al., 1999 and Krishnamurthy et al., 2000; human 
metapneumovirus, Biacchesi et al., 2004a and Herfst et al., 2004; and avian metapneumovirus, 
Naylor et al., 2004 and Govindarajan et al., 2006).  There are many downstream applications of 
reverse genetics technology such as development of vaccines and vaccine vectors and use as a 




APMV-2 was established which was then used to study the role of F protein cleavage site in 
virus biology and pathogenesis.  
 
1.3 Research Objectives: 
 
1. Determination and comparison of complete genome sequences of APMV- 2 
           prototype strain Yucaipa and strains Bangor, England and Kenya.  
 
2. Comparison of the pathogenicity of APMV-2 strains Yucaipa and Bangor in chickens  
           and turkeys. 
 
3. Establishment of a reverse genetics system for APMV-2 and recovery of   
           infectious recombinant APMV-2/Yuc expressing a foreign gene.  
 
4. Study of the role of amino acid composition at the fusion protein cleavage   

















            Review of Literature 
 
2.2 Classification 
APMV-2 belongs to the genus Avulavirus within the subfamily Paramyxovirinae in the 
family Paramyxoviridae under the order Mononegavirales (Lamb and Parks, 2007). 
Paramyxoviruses are divided into two subfamilies, Paramyxovirinae and Pneumovirinae, based 
on structure, genome organization, and sequence relatedness (Lamb and Parks, 2007). Subfamily 
Paramyxovirinae comprises five genera: Respirovirus (i.e., Sendai virus [SeV] and human 
parainfluenza virus types 1 and 3 [HPIV-1 and -3]),  Rubulavirus (i.e., simian virus type 5 [SV5], 
mumps virus [MuV], and human parainfluenza virus types 2 and 4 [HPIV-2 and -4]), 
Morbillivirus (i.e., measles [MeV] and canine distemper [CDV] viruses), Henipavirus (i.e., 
Hendra [HeV] and Nipah [NiV] viruses), and Avulavirus (comprising the nine serotypes of avian 
paramyxoviruses [APMV-1 to -9]). Subfamily Pneumovirinae contains two genera, Pneumovirus 
(comprising human respiratory syncytial virus [HRSV] and its animal counterparts) and 
Metapneumovirus (comprising human metapneumovirus [HMPV] and its avian counterpart 
[AMPV]. The genus Avulavirus consists of paramyxoviruses particularly isolated from avian 
species except for avian metapneumovirus.  These viruses have been classified into nine 
serotypes (APMV serotypes 1 through 9) based on hemagglutination inhibition (HI) and 
neuraminidase inhibition (NI) tests (Alexander 2003). The economically important poultry 





APMV-2 is a pleomorphic and enveloped virus with diameter ranging between 100 to 
300 nm, which is similar to NDV (Fig. 2.1, 2.2). The paramyxoviral envelope is derived from 
host cell membrane and encloses a helical nucleocapsid.  The outer surface of the envelope 
consists of two viral spike glycoproteins, namely fusion (F) and hemagglutination neuraminidase 
(HN) proteins. The F protein aids in the fusion of virion with the host cell membrane in a pH-
independent mechanism while the HN protein is required for the attachment of the virion to host 
cell. Under the envelope lies the matrix protein (M) which is shown to play major roles in virus 
assembly and budding in NDV. The envelope encloses the ribo-nucleocapsid core structure or 
the transcriptive-replicative complex, formed by nucleocapsid protein (N) bound to the genomic 
RNA; also attached to this structure are the phosphoprotein (P) and large polymerase (L) protein 
(Lamb and Parks, 2007). The viral RNA genome is single stranded, non-segmented and 
negative-sensed.  
                                                 
 
Fig. 2.1 Schematic diagram of a virion of Avian Paramyxovirus serotype 2 (not drawn to scale). 
N, Nucleocapsid protein; P, Phosphoprotein; M, Matrix protein; L, Large polymerase protein; F, 




                                                  
Fig. 2.2 Electron micrograph of negatively stained pleomorphic Avian Paramyxovirus serotype 2 
(strain Yucaipa).  
The supernatant of APMV-2 strain Yucaipa infected chicken embryo fibroblast cells were 
collected four days post infection and following clarification at 4000 rpm for 10 min, negative 
staining was performed and observed under electron microscope. 
 
2.4 Genome organization 
 
The APMV-2 genome contains six genes in tandem and encodes upto eight proteins. 
These genes are arranged in a linear order, 3‟-NP-P-M-F-HN-L-5‟ as shown in Fig. 2.3. On each 
end of the genome is a 3‟ and 5‟ extracistronic sequence, known as the leader and trailer, 
respectively. The leader and trailer regions are cis-acting regulatory elements involved in 
replication, transcription and packaging of the genomic and antigenomic RNAs. Each gene is 
flanked by conserved transcriptional control sequences, known as the gene start (GS) and gene 
end (GE), respectively which are followed by 5‟ and 3‟ untranslated regions (UTR). Non-coding 






Fig. 2.3 Genome organization of APMV-2 and schematic diagram of a gene cassette. 
The single-stranded, negative-sense genome RNA has leader sequence at 3‟ end and a trailer 
sequence at 5‟ end. The N, P, M, F, HN and L genes are arranged in tandem. Each gene is 
flanked by conserved gene start and gene end and has untranslated sequences at 3‟ and 5‟ regions 
of the ORF between each gene boundary.  
 
 
2.5 Viral proteins 
 
The genome of APMV-2 consists of six genes N, P, M, F, HN and L encoding upto eight 
proteins: N, P, V, W, M, F, HN and L (Subbiah et al., 2008). The two proteins, V and W, are 
generated by stuttering of the viral RNA polymerase, known as RNA editing, wherein non-
templated G residue(s) get inserted into P gene (Steward et al., 1993). The genomic structure and 
proteins of APMV-2 are known to be similar to those of APMV-1 and other paramyxoviruses; 
hence, the knowledge about the APMV-2 proteins is derived from studies done with other 




2.5.1 Nucleocapsid and its associated proteins 
The nucleocapsid protein (N): It is tightly bound with viral genomic RNA and forms 
the nucleocapsid core. Two other viral proteins, the phosphoprotein (P) and the large polymerase 
protein (L) are loosely attached to this core and together form the transcriptive-replicative 
complex or the active polymerase complex which is the minimum infectious unit of the virus 
(Lamb and Parks, 2007). The N protein bind to viral genomic RNA and make it RNase resistant. 
The N protein interacts with P and L proteins during transcription and replication and with M 
protein during virus assembly. The intracellular level of unassembled N protein regulates the 
switching of viral transcription to replication of the viral genome (Blumberg and Kolakofsky, 
1981; Blumberg et al., 1981). 
P, V and W proteins: The P protein produced from unedited P mRNA is acidic and the 
heavily phosphorylated viral protein (McGinnes et al., 1988; Steward et al., 1993). The P protein 
along with N and L forms viral polymerase complex.  It prevents nonspecific assembly or self 
aggregation of N proteins. The non-structural V and W proteins are produced by 
cotranscriptional insertions of one or two G residues, respectively, at the editing site of the P 
gene ORF (Lamb and Parks, 2007; Steward et al., 1993). The V protein has anti-interferon-alpha 
activity in NDV, while the function of W protein is still unknown (Huang et al., 2003) 
L protein: The L protein is the largest structural protein but least abundant in the virion 
core (about 50 copies per virion). It is the major component of the viral RNA dependent RNA 
polymerase (Banerjee, 1987; Tordo et al., 1988). In general, the L protein has 5‟ capping and 3‟ 
polyadenylation activities on viral mRNAs. Further, the L protein has been shown to be a 





2.5.2 Matrix protein 
The M protein is the most abundant protein in the virion. It functions as the central 
organizer of viral morphogenesis and has been found to interact with the cytoplasmic tails of the 
integral membrane proteins, the lipid bilayer and the nucleocapsid. The self-association of M 
proteins and its affinity to interact with the nucleocapsid might be the driving force for forming a 
budding virus particle (Peeples, 1991). 
 
2.5.3 Envelope glycoproteins 
APMV-2 envelope has two integral membrane glycoproteins namely, the fusion (F) 
glycoprotein that mediates pH-independent fusion of the viral envelope with the plasma 
membrane of the host cell and the hemagglutinin-neuraminidase (HN) glycoprotein that aides in 
the attachment of the virus to host cell membrane. 
F protein: The F protein mediates fusion between cells causing giant cell formation 
(syncytia) and also fusion between the virus envelope and host cell plasma membrane, in a pH-
independent manner. This forms pores on plasma membrane through which the viral 
nucleocapsid is delivered into the host cell. The fusion and syncytia formation caused by F 
protein of the virus is one of the important factors for virulence as well as viral spread within 
infected host. The F protein is a type I integral membrane protein and is synthesized as an 
inactive precursor (F0), which is cleaved by using host-cell proteolytic enzyme(s). This cleavage 
results in biologically active protein that has two subunits F1 and F2 interconnected by disulfide 
bond (Scheid and Choppin, 1974). In NDV, F protein is synthesized on rough endoplasmic 
reticulum and targeted towards host cell membrane for expression. The NDV strains that have 




like proteases, whereas, those NDV strains that have a single basic amino acid at their F protein 
cleavage site require exogenous proteases for cleavage activation (Ortmann et al., 1994; Scheid 
and Choppin, 1974).  
Several studies have shown that the amino acid sequence at F protein cleavage site is the 
major virulence determinant of NDV; the avirulent strains of NDV have a monobasic amino acid 
residue at F protein cleavage site and a leucine at the F1 N terminus, while virulent NDV strains 
possess multiple basic amino acids at F protein cleavage site and a phenylalanine at the F1 N 
terminus (Nagai
 
et al., 1976; Ogasawara et al., 1992). Accordingly, the World Organization of 
Animal Health considers the presence of multiple basic amino acids and phenylalanine at the F 
protein cleavage site as one of the important criteria to categorize NDV strains under virulent 
pathotype (OIE, Chapter 2.1.15).  The F protein cleavage site of APMV-2 has two basic amino 
acids and a phenylalanine at F1 N terminus but is still avirulent in chickens (Subbiah et al., 
2008). The recently available complete genome sequences of other APMV serotypes show that 
each APMV serotype has unique F protein cleavage site and does not seem to follow the general 
rule as seen with NDV strains. 
HN protein: The HN protein is a type II integral membrane protein. The C-terminus end 
is the globular head which is the site for the attachment of virus to the host cells via sialic acid 
containing host receptors. The HN protein also cleaves sialic acid enzymatically (neuraminidase 
activity), thus assisting virus release from surface (Crennell et al., 2000). In addition it has been 





2.6 Stages of APMV-2 replication 
        The replication of APMV-2 is very similar to that of other paramyxoviruses (Fig. 2.4). 
Fig. 2.4 Stages of replication in a Paramyxovirus.  
Schematic diagram of stages of replication in a paramyxovirus, adapted from 
http://www.urmc.rochester.edu/SMD/mbi/education/courses/MBI456files/ParamyxovirusII.pdf  
 
2.6.1 Virus attachment, fusion and entry 
The initial step of APMV-2 infection is the attachment of the virus to host cell receptor 
mediated by HN protein (Huang et al., 1980). The next step is fusion of viral envelope with the 
host cell plasma membrane at neutral pH mediated by F protein and subsequently the release of 







The negative-sense RNA genomes of paramyxoviruses are non-infectious, because 
uninfected host cells lack RNA-dependent RNA polymerase (RDRP) activity. The viral mRNA 
transcription occurs in cytoplasm. The viral RDRP complex enters the 3‟ end of viral genome 
promoter, i.e. leader, and synthesizes short (+) strand leader RNA followed by re-initiation of N 
gene mRNA synthesis from N gene start sequence. The transcription in most cases terminates at 
the GE sequence, but some of RDRP continue to transcribe the downstream genes. The 
sequential start and stop mechanism results in a gradient mRNA production with higher 
concentration of the most 3‟ proximal gene than those of downstream (Cattaneo et al., 1987). 
The mRNA are capped and polyadenylated.  The intergenic regions located between each gene 
are not transcribed. The optimal length of the intergenic sequences has been shown to be 
required for the efficient transcription of each downstream gene (Yan and Samal, 2008).  
 
2.6.3 Genome replication 
The concentration of viral proteins, particularly, N protein determines the switch of 
RDRP from transcription mode to replication of viral genome. A full length complimentary copy 
known as (+) antigenome is first produced by ignoring all the start-stop signals (Blumberg and 
Kolakofsky, 1981; Nagai, 1999). These (+) antigenomes are used as templates for synthesis of (-) 
genome for packaging into the new viral progenies. It has been shown that the leader and trailer 
regions contain specific signals for encapsidation (Blumberg and Kolakofsky, 1981). The RNA 





Fig. 2.5 Schematic diagram of RNA replication and transcription in paramyxovirus. 
Schematic diagram showing transcription and replication of a paramyxovirus. Genome and 
antigenome are shown encapsidated by nucleocapsid protein subunits (ovals). The vertical lines 
indicate the gene junctions. The polymerase complex (P-L complex) transcribes the genome to 
yield capped and poly A-tailed mRNAs. When sufficient amount of viral protein levels are 
achieved, the viral polymerase switches from its transcription mode to replicative mode to 
produce antigenome, which serves as the template for the synthesis of the progeny viral genome.  
 
 2.6.4 Virus assembly and release 
The nucleocapsid core assembly occurs in the cytoplasm of host cell. Initially, free N 
protein subunits encapsidate the viral genomic RNA and form a helical ribonucleoprotein (RNP) 
structure, subsequently, the P and L proteins loosely bind to the RNP forming transcriptase 
complex (Kingsbury et al., 1978). The membrane glycoproteins (F and HN) synthesized on 
rough endoplasmic reticulum (ER) undergo conformational maturation before getting transported 




reach the Golgi apparatus for post translational modifications, such as modification of 
carbohydrate chains of HN protein and cleavage of multiple basic cleavage sites of F protein. 
The glycoproteins are transported to the cell surface via vesicles where the assembly of the virus 
envelope occurs (Doms et al., 1993; Feller et al., 1969).  The M protein has a major role in 
bringing the assembled RNP core to the appropriate place at the plasma membrane (Peeples, 
1991). The cytoplasmic tails of F and HN glycoproteins interact with M proteins, which in turn 
associate with the nucleocapsid thus helping the process of budding of the mature virions. 
 
2.7 Epidemiology of APMV-2 infections 
APMV-2 was first isolated from a diseased chicken in Yucaipa, California (Bankowski et 
al., 1960). Subsequently, many APMV-2 infections have been reported in chickens, turkeys, 
racing pigeons and feral birds across the globe (Alexander et al.,  1982; Asahara et al.,  1973; 
Collings et al.,  1975; Fleury et al.,  1979; Goodman et al.,  1988; Lang et al.,  1975; Lipkind et 
al.,  1979; Lipkind et al.,  1981; Lipkind et al.,  1982; Mbugua et al.,  1985; Nymadawa et al.,  
1977; Shihmanter et al.,  1997; Weisman et al.,  1984). APMV-2 strains are endemic among 
passeriformes and psittacines in Senegal and on the island of Hiddensee, GDR, in the Baltic Sea 
(Alexander, 1993, Fleury & Alexander, 1979, Nymadava et al., 1977). The prevalence of 
APMV-2 antibodies has been studied in different avian species including commercial poultry 
(Ley et al., 2000; Zhang et al., 2007; Warke et al., 2008). Furthermore, APMV-2 strains have 
been isolated from chickens; broilers and layers in USA, Canada, Russia, Japan, Israel, India, 
Saudi Arabia, Great Britain and Costa Rica, and from turkeys in the USA, Canada, Israel, France 
and Italy (Wood et al., 2008).  Serological surveys of poultry in the USA indicated that this virus 




Jensen, 1979). APMV-2 infection induced more severe symptoms in turkeys than in chickens 
(Alexander, 1993). APMV-2 has been shown to affect the hatchability and poult yield of turkeys 
(Bankowski et al., 1981). However, more serious disease has been reported, especially in turkeys 
during secondary bacterial infections (Lang et al., 1975 and Yegana et al., 1985). Virus isolation 
and the presence of antibodies have also indicated the presence of APMV-2 infections in turkey 
flocks without causing any clinical disease (Bradshaw & Jensen, 1979). APMV-2 isolated from 
commercial layer farms and from broiler breeder farms in Scotland was suspected to be the cause 
for drop in egg production (Wood et al., 2008).  
 
2.8 Reverse genetics 
In negative-sense RNA viruses, the naked viral genome is non-infectious because the 
uninfected cells do not have RDRP required for the synthesis of viral proteins. The RDRP 
complex is virally encoded and packaged into the virion particles. Reverse genetics is a method 
of generation of infectious virus from entirely cloned cDNA of the viral genome. In this system 
plasmids expressing viral proteins N, P and L and full length antigenome are transfected in cells. 
All these plasmids are under the control of T7 RNA polymerase promoter. The T7 RNA 
polymerase is either provided by a recombinant vaccinia virus expressing bacteriophage T7 RNA 
polymerase or constitutively expressed in the cell line like BHK T7. This technique helps to 
manipulate and genetically engineer viruses.  
The rabies virus was the first successfully recovered virus using this approach (Schnell et 
al., 1994). Several other viruses such as the vesicular stomatitis virus (Lawson et al.,1995; 
Whelan et al., 1995), simian virus 5 (He et al., 1997), human respiratory syncytial virus (Collins 




Barrett, 1997), parainfluenza virus (Durbin et al., 1997; Hoffmann and Banerjee, 1997), measles 
virus (Radecke et al., 1995) and Nipah virus (Yoneda et al., 2006) have been recovered by 
similar approach. The recoveries of infectious NDVs from cDNA using reverse genetics system 
were first reported in 1999 (Romer-Oberdorfer et al., 1999; Peeters et al., 1999). The reverse 
genetics systems available for NDV are: lentogenic strain LaSota (Huang et al., 2001; Romer 
Oberdorfer et al., 1999 ; Peeters et al., 1999), B1 (Nakaya et al., 2001) , mesogenic strain 
Beaudette C (Krishnamurthy et al., 2000) and velogenic strain Hert/33 (de Leeuw et al., 2005). 
The reverse genetics system has been used to study of molecular determinants of viral 






 Determination of the complete genome sequences of four strains of avian paramyxovirus 
serotype 2: Evidence of existence of two subgroups within serotype 2 
(Complete genome sequence of APMV-2 strain Yucaipa was previously published as: 
Subbiah et al., 2008. Virus Res 137: 40-48.) 
 
3.2 Abstract 
The complete consensus genome sequences of avian paramyxovirus (APMV) serotype 2 
strains Bangor, England and Kenya were determined and the sequences were compared with 
those of APMV-2 prototype strain Yucaipa and other paramyxoviruses. The complete genome 
sequence of strain Yucaipa was initially determined and published (Subbiah et al., 2008. Virus 
Res 137: 40-48). The genome lengths of APMV-2 strains Yucaipa, Bangor, England and Kenya 
are 14904, 15024, 14904, 14916 nucleotides (nt), respectively. Each genome consists of six non-




, with a 55-nt leader at the 3‟end. The 
lengths of trailer at the 5‟ end of the strains Yucaipa, Bangor, England, Kenya are 154, 173, 154 
and 154 nt, respectively. In general, sequence comparison of APMV-2 strains England and 
Kenya with strain Yucaipa show 94–98% nt and 90–100% aggregate amino acid (aa) identities.  
However, strain Bangor shares low level of genome and predicted aa sequence identities with the 











found in those of 
other three strains. Reciprocal cross-hemagglutination inhibition (HI) and cross-neutralization 




the other APMV-2 strains, but with 4- to 8-fold lower HI titers. Taken together, our results 
indicated that these four APMV-2 strains represent a single serotype with two subgroups based 
on nt and aa sequence analyses and by cross-HI and cross-neutralization assays.  
 
3.3 Introduction 
The family Paramyxoviridae is large and diverse and includes members that have been 
isolated from many species of avian, terrestrial, and aquatic animals around the world (Lamb and 
Parks, 2007; Wang and Eaton, 2001). Paramyxoviruses are pleomorphic, enveloped, cytoplasmic 
viruses with a non-segmented negative-strand RNA genome. Paramyxoviruses are divided into 
two subfamilies, Paramyxovirinae and Pneumovirinae, based on structure, genome organization, 
and sequence relatedness (Lamb et al., 2005). Subfamily Paramyxovirinae comprises five 
genera; Respirovirus (including Sendai virus [SeV] and human parainfluenza virus types 1 and 3 
[HPIV-1 and -3]), Rubulavirus (including simian virus type 5 [SV5], mumps virus [MuV], and 
human parainfluenza virus types 2 and 4 [HPIV-2 and -4]), Morbillivirus (including measles 
[MeV] and canine distemper [CDV] viruses), Henipavirus (including Hendra [HeV] and Nipah 
[NiV] viruses), and Avulavirus (comprising the nine serotypes of avian paramyxoviruses 
[APMV-1 to -9]). Subfamily Pneumovirinae contains two genera, Pneumovirus (comprising 
human respiratory syncytial virus [HRSV] and its animal counterparts) and Metapneumovirus 
(comprising human metapneumovirus [HMPV] and its avian counterpart [AMPV].  
The genome lengths of paramyxoviruses range from 15 to 19 kb and contain 6–10 genes 
arranged in tandem (Lamb and Parks, 2007). All paramyxoviruses examined to date encode a 
major nucleocapsid protein (N) that binds the entire length of the genomic and antigenomic 




is the major polymerase subunit and bears catalytic domains, a matrix protein (M) that lines the 
inner surface of the envelope, a fusion glycoprotein (F) that is a surface antigen that mediates 
viral penetration and syncytium formation and a major glycoprotein (G) or hemagglutinin-
neuraminidase (HN) glycoprotein that is a second surface antigen and mediates attachment. Most 
members of subfamily Paramyxovirinae engage in RNA editing, whereby a specific motif in the 
P gene directs non-templated addition of one or more nucleotides to a proportion of P transcripts. 
This produces mRNA subpopulations containing frameshifts generating one or more alternate 
internal ORFs to produce chimeric proteins in which the upstream end is encoded by the P ORF 
and the downstream end is encoded by the alternative ORF. The insertion of a single G residue at 
the P editing site alters the reading frame and produces V protein, in which the downstream 
domain contains a highly conserved cysteine motif. The V protein has been implicated in the 
regulation of viral RNA synthesis (Horikami et al., 1996; Lin et al., 2005) and in counteracting 
host antiviral responses (Goodbourn et al., 2000). Alternatively, the insertion of two G residues 
shifts the reading frame to access an internal ORF that leads to production of the W protein, 
whose function is not yet understood (Steward et al., 1993).  
The APMVs have been classified into nine different serotypes based on hemagglutination 
inhibition (HI) and neuraminidase inhibition (NI) assays (Alexander, 2003). Newcastle disease 
virus (NDV) belongs to serotype 1. NDV is the most characterized member among all the 
APMV serotypes because it produces severe disease in chickens (Alexander, 1980). The APMV-
2 was first isolated in 1956 in Yucaipa, California from a diseased chicken that was also infected 
with infectious laryngotracheitis virus (Bankowski et al., 1960). Since then many APMV-2 
strains have been isolated from chickens, turkeys and feral birds around the world (Alexander et 




Hanson, 1988; Lang et al., 1975; Lipkind et al., 1979, 1982; Mbugua and Karstad, 1985; 
Nymadawa et al., 1977; Shihmanter et al., 1997; Weisman et al., 1984; Zhang et al., 2006, 
2007). APMV-2 strain Bangor was isolated from a finch during a routine quarantine evaluation 
and the biological and serological characterization suggested placing strain Bangor as a separate 
serotype or as a subgroup within serotype 2 (McFerran et al., 1973; McFerran et al., 1974). 
As noted, APMV-2 strains have been isolated from a wide variety of avian species from 
different parts of the world. But little is known about the serological and genetic relationships 
among these strains. The information is important for understanding virus evolution and 
epidemiology and for development of vaccines against these viruses. To date, the complete 
genome sequences of only the prototype strain Yucaipa is available (Subbiah et al., 2008). As a 
first step towards understanding the serological and genetic relationship among APMV-2 strains, 
we have determined the complete genome sequences of three other strains of APMV-2; Bangor, 
England and Kenya, isolated from a finch, a chicken and a gadwell, respectively, and describe 
comparison with the complete genome sequence of prototype strain Yucaipa and other 
paramyxoviruses. Our sequence and antigenic analyses suggested that APMV- 2 strains can be 
classified into two genetic subgroups under a single serotype.  
 
3.4 Materials and methods:  
 
3.4.1 Virus and cells. APMV-2/Chicken/Yucaipa/Cal/56 (APMV-2 Yucaipa) and APMV-
2/Finch/N.Ireland/Bangor/73   (APMV-2 Bangor) were received from the National Veterinary 
Services Laboratory, Ames, Iowa, USA and APMV-2/Chicken/England/7702/06 (APMV-2 




Laboratories Agency, Weybridge, UK. The viruses were grown in 9-day-old embryonated, 
specific pathogen-free (SPF) chicken eggs. Hemagglutination (HA) titers were determined using 
0.5% chicken RBC at room temperature.  The ability of the viruses to replicate in cell culture 
was examined in two established cell lines- DF1, chicken fibroblast and Vero, African green 
monkey kidney. Both the cell lines were grown in Dulbecco‟s MEM containing 10% fetal bovine 
serum (FBS) in a 37
◦
C incubator with 5% CO2.  
 
3.4.2 Replication of viruses in cell cultures. The cell monolayers (DF1 and Vero) were infected 
with a 10
−3
 dilution of 2
8
 HA units of egg-grown APMV-2 strains Yucaipa, Bangor, England and 
Kenya and, after 1 h of adsorption, the viral inoculum was replaced with maintenance medium 
containing 2% FBS with or without the supplementation of exogenous protease (10% allantoic 
fluid). The cells were observed daily for cytopathic effects (CPE) and the supernatants of the 
infected cells were collected every 24 h until fifth day post-infection (dpi).  Virus titers were 
determined by serial end-point dilution on monolayers of DF1 cells in 96-well plates. The 
infected cells were immunostained using polyclonal antisera raised against the viruses in 
chickens. Virus titers (TCID50/ml) were calculated using Reed & Muench method (Reed & 
Muench, 1938). The ability of the viruses to produce plaques was tested in both the cell lines 
under various conditions, including 1% methylcellulose, 1% low melting agar, and 0.8% noble 
agar with or without magnesium sulfate (25 mM) and 1% diethylaminoethyl dextran (30 µg/ml). 
Plaques were visualized by staining with either crystal violet or neutral red. 
              
3.4.3 Serological analysis. Antisera against APMV-2 strains Yucaipa, Bangor, England and 




intranasal (IN) routes mimicking natural infection. Briefly, groups of three 2-week-old chickens 
of each group were infected with each virus (2
8
 HAU) at separate times to avoid cross-infection. 
Two weeks after infection the chickens were bled and sera were collected and stored at −20
◦
C. 
HN-specific antibody titers in the serum samples were determined by HI assay using chicken 
RBC as described previously (Alexander, 1997). The cross-reactivity of immunized chicken sera 
was determined by HI assay against heterologous APMV-2 strains. The ability of immunized 
chicken sera to cross-neutralize heterologous APMV-2 strains was determined by focus 
reduction microneutralization assay using standard procedures (Borisevich et al., 2007). Briefly, 
different dilutions of sera were mixed with constant titer of virus (10
3
 TCID50/ml), incubated for 
2 h at room temperature and transferred to monolayer of DF1 cells in 96-well plates. The plates 
were incubated for three days at 37
◦
C with 5% CO2. Each plate included both uninfected and 
infected cell controls. On the third day, the culture medium was removed and cells were fixed 
with methanol for 30 min and washed with PBS three times. The fixed cells were immunostained 
and a 50% focus reduction was considered as the end point of the titration.  
 
3.4.4 Pathogenicity tests. The virulence of the APMV-2 strains was determined by two standard 
pathogenicity tests for APMV-1: mean death time (MDT) in 9-day-old embryonated SPF 
chicken eggs and intracerebral pathogenicity index (ICPI) test in 1-day-old SPF chicks 




) dilutions of fresh infective 
allantoic fluid in PBS was made and 0.1 ml of each diluent was inoculated into the allantoic 
cavities of five 9-day-old SPF embryonated chicken eggs (BEE eggs company, PA), which were 
incubated at 37
o
C. The eggs were candled 3 times a day for the next 7 days and the time of 




dilution that kills all the embryos. The MDT is the mean time in hours for the MLD to kill all the 
inoculated embryos. The MDT has been used to classify APMV-1 strains into the following 
groups: velogenic strains (taking less than 60 h to kill); mesogenic strains (taking 60-90 h to 
kill); and lentogenic strains (taking more than 90 h to kill). 
For ICPI, 0.05 ml (1:10 dilution) of fresh infective allantoic fluid of each virus was 
inoculated into groups of ten 1-day-old SPF chicks via the intracerebral route. The inoculation 
was done using a 27-gauge needle attached to a 1 ml stepper syringe dispenser that was set to 
dispense 0.05 ml of inoculum per bird. The birds were inoculated by inserting the needle up to 
the hub into the right or left rear quadrant of the cranium. The birds were observed for clinical 
symptoms and mortality once every 8 h for a period of 10 days. At each observation, the birds 
were scored: 0, if normal, 1, if sick and 2, if dead. ICPI is the mean score per bird per 
observation over the 10-day period. Highly virulent (velogenic) viruses give values approaching 
2, and avirulent (lentogenic) viruses give values close to 0.  
 
3.4.5 Virus RNA isolation and complete genome sequencing. The viral RNA was isolated 
from the allantoic fluid of virus-infected eggs using RNeasy kit according to the manufacturer‟s 
instructions (QIAGEN, USA). The complete genome sequence exclusive of the termini of strain 
Yucaipa was determined using a combination of three different strategies (Subbiah et al., 2008). 
First, the nucleotide sequences of the N genes of all the available rubulaviruses and avulaviruses 
were aligned to identify a consensus sequence that was used to design the forward primer N-451 
(5_-GAAGATGATGCACCAGAAGA, numbered according to the consensus sequence). 
Similarly, L genes of rubulaviruses and avulaviruses were aligned to design two reverse 




NGGNCCRAARTGNCKYTGNGGNGGRTT (N = A/C/G/T, R = A/G, K= G/T, Y = C/T) and 
L-6960r, 5‟- NSWRTARTANCCYTTNGCNGCRTTNCCDATNGT (N= A/C/G/T, S = G/C, 
W= A/T, R = A/G, Y = C/T, D= G/A/T). A reverse primer from the APMV-2 F gene sequence 
available in GenBank (accession no. AF422844) (F-127r, 5‟-ACTGCGATGGTCCCTGTGAG, 
numbered according to the Yucaipa strain F gene sequence) and APMV-2 L genes pecific 
forward primers from the partial sequence available in GenBank (accession no. AF515835) were 
designed. Second, a gene-start forward primer (5‟GGAAAACTTGGGGGCGACA) containing 
the presumptively conserved gene-start sequence at its 3‟end (underlined) and a reverse primer 
(5‟TTTTTTCTTAAACCAGGCTTC) with the presumptively conserved gene-end sequence at 
its 5‟end (underlined) were designed. RT-PCR with these primers yielded different regions of all 
the viral genes. Finally, as the third strategy, most of the L gene was sequenced by primer 
walking. Briefly, cDNA synthesized from an RT reaction with an L gene-specific forward primer 
was tailed using 3‟ poly-C tail with terminal deoxynucleotidyl transferase (Invitrogen). The dC-
tailed cDNA was amplified by PCR using an L gene-specific forward primer and a poly dG-
containing reverse primer. The PCR-amplified products were cloned and sequenced. Most parts 
of genomes of the other APMV-2 strains except the 3‟ and 5‟ termini were amplified into cDNAs 
using primers designed from the published APMV-2 strain Yucaipa (Table 3.1). The sequences 
of the 3‟ and 5‟ genomic ends were determined from cDNA prepared by rapid amplification of 
cDNA ends (RACE) as described previously (Subbiah et al., 2008, Troutt et al., 1992). Briefly, 





), was ligated to viral RNA and to 
determine the 5‟ end, cDNA derived using L gene specific forward primer was ligated with the 




µl of RNA oligonucleotide (50 pmol) were denatured at 65
◦
C for 5 min and snap frozen on dry 
ice. The ligation reaction was carried out overnight at 16
◦
C with 4 µl of 10× T4 RNA ligase 
buffer, 10 units of T4 RNA ligase (Promega, USA), 1mM hexamine cobalt chloride, 10 µg/ml 
BSA, 25% (w/v) of PEG 8000 and RNase-free water to make a 40 µl reaction mixture. Ligation 
was terminated by heating to 65
◦
C for 20 min. The adaptor primer (5‟-
GAAGAGAAGGTGGAAATGGCGTTTTGG) complimentary to the RNA oligo, was then used 













Gene End reverse Gene end consensus 
*
NNNNNNNNNNNTTTTTTCTTAA 
N Forward 388-415 ACATGCGAGCTCACGCAACCCTTGCAGC 
N Reverse 1019-1044 GCCTGATCAAGGACGACATCTTCTTC 
P Forward 1758-1781 CGAAGTCAAGGGCCCGCAAACAAC 
P Reverse 2464-2484 CTGACTAATCTCATTCTTTAT 
M Forward 3135-3157 CCAAAGAGTTGCAGCAGCAAATC 
F Forward 5217-5242 AGTGTCACTACACCAAAAGGAGAAGG 
HN Forward 6698-6719 CCAGTATGTATATCTCTCTGGG 
L1 Forward 8869-8890 ATGCTAGTGAGACACACGCAGG 
L1 Reverse 10422-10441 GAATACACAAAGAATGATTG 
L2 Forward 11967-11986 ATATATCAGCAAATCATGCT 
L2 Reverse 13314-13332 CAGCATACTTGTACCAGCT 
L3 Forward 14170-14186 TCACCCTATTCGGACAG 
 
 
Table 3.1. Primers used to amplify APMV-2 genome based on previously available genome 







3.4.6 Virus genome sequence alignment and phylogenetic analyses. Sequence compilation 
and prediction of ORFs were carried out using the SeqMan and EditSeq programs in the 
Lasergene 6 (DNASTAR) software package (www.dnastar.com). The search for matching 
protein sequences in GenBank was done using the blastp program of the same package. The 
bootstrap values in phylogenetic tree were calculated using 1000 replicas and the construction of 
phylogenetic trees was performed by maximum parsimony method using MEGA 4 software 
(Tamura et al., 2007).  
 
3.4.7 Database accession numbers. The complete genome sequences of APMV-2 strains 
Bangor, England and Kenya were submitted to GenBank (accession number HM159995, 
HM159993 and HM159994, respectively). Accession numbers for other paramyxovirus 
sequences used in this study were: Avulaviruses: APMV-1, AF077761; APMV-2 strain Yucaipa, 
EU338414; APMV-3, EU403085; APMV-4KR, EU877976; APMV-4HK, FJ177514; APMV-
6TW, NC 003043; APMV-6HK, EU622637; APMV-6FE, EF569970; APMV-7, FJ231524; 
APMV-8DEL, FJ215863; APMV-8WAK, FJ215864; APMV-9, EU910942. Rubulaviruses: 
hPIV-2, NC_003443; PIV5 (also known as SV-5), NC_006430; MuV, NC_002200; simian virus 
41 (SV41), NC_006428. Respiroviruses: hPIV-1, NC_003461; hPIV-3, NC_001796; 
SeV, NC_001552, BPIV-3, NC_002161. Henipaviruses: NiV, NC_002728; HeV, NC_001906. 
Morbilliviruses: CDV, NC_001921; MeV, AF266288; phocine distemper virus 
(PDV), NC_006383; rinderpest virus (RPV), NC_006296; peste des petits ruminants virus 
(PPRV), NC_006383; dolphin morbillivirus (DMV), NC_005283; other paramyxovirus: Atlantic 
salmon paramyxovirus (ASPV), EF646380; Beilong virus (BeV), NC_007803; Fer-de-Lance 




Mossman (MoV), NC_005339; Tupaia paramyxovirus (TpV), NC_002199; Pneumoviruses: 





3.5.1 In vitro growth characteristics of APMV-2 strains Yucaipa, Bangor, England and 





units in 9-day-old embryonated SPF chickens eggs at 4 dpi. The inclusion of exogenous protease, 
either 10% allantoic fluid or trypsin, was not necessary for replication of these viruses in cell 
culture indicating a lack of requirement of external proteases for efficient cleavage of the F 
protein. The viruses grew more efficiently in DF1 cells than in Vero cells. Viral CPE involved 
rounding and detachment of the cells. The growth kinetics and the CPE of all the three strains 
were similar to those of APMV-2 prototype strain Yucaipa. None of the strains produced 
syncytia or formed plaques but caused single cell infections similar to that of APMV-2 strain 







Fig. 3.1. Single cell infection caused by APMV-2 strains Yucaipa, Bangor, England and Kenya 
in DF1 and Vero cells, three days post infection. The infected cells were immunostained using 
single-infection sera raised specifically against each of these strains in chickens.  
 
3.5.2 Antigenic relationship among APMV-2 strains. The antigenic relationship among 
APMV-2 strains Yucaipa, Bangor, England and Kenya was evaluated by reciprocal HI tests 
using strain specific convalescent sera raised by a single infection of chickens via the IN/IO 
route. Each of the antiserum exhibited a 2- to 16-fold difference in HI titer between the 
homologous and heterologous strains (Table 3.2). The HI titer of the APMV-2 prototype strain 
Yucaipa was 8-, 4-, and 4-fold higher against homologous strain Yucaipa than against strains 
Bangor, England and Kenya, respectively. Conversely, the HI titer of antisera specifically against 
strains Bangor, England and Kenya were 4-, 4- and 8-fold higher against the homologous strains 
than against the prototype strain Yucaipa. The antiserum against strain Bangor showed 2-fold 
higher HI titer against strain Bangor than against strains England and Kenya. The antiserum 




against strain Bangor. The antiserum specific for strain Kenya showed 16- and 2- fold higher 
titers against homologous strain Kenya than against strains Bangor and England, respectively.  
The ability of antisera to neutralize homologous and heterologous APMV-2 strains was 
assessed by microneutralization assay in DF1 cells. The antiserum specific for strain Yucaipa 
showed 4-fold higher neutralization titer against homologous strain Yucaipa and strains England 
and Kenya than against strain Bangor. On the contrary, antisera specific for strain Bangor 
showed 4-fold higher neutralization titer against homologous strain Bangor than against 
prototype strain Yucaipa and 2-fold higher neutralization titer against homologous strain Bangor 
than against strains England and Kenya. The antisera specific to strains England and Kenya 
showed 4-fold higher neutralization titers against their homologous strains compared to those 
against strains Yucaipa and Bangor, while showing 2-fold difference between either of the 
strains. (Table 3.2). These reactions indicated existence of a low level of antigenic differences 
among APMV-2 strains. Our results suggested that the strains Yucaipa, England and Kenya 















Table 3.2. Antigenic analyses of APMV-2 strains Yucaipa, Bangor, England and Kenya using 
antisera from chickens infected with individual strains.  
a  
Cross HI titer is the reciprocal of the highest dilution of antisera that inhibited 4 HA units of the  
virus.  
b
 Neutralization titer was defined as the reciprocal of highest dilution of antisera that caused 50% 
reduction in the focus compared to the positive control wells.  
 
3.5.3 The pathogenicity of APMV-2 strains. The pathogenicity of APMV-2 strains Yucaipa, 
Bangor, England and Kenya were evaluated by MDT in 9-day-old embryonated SPF chicken 
eggs and ICPI test in 1-day-old chicks. The MDT and ICPI values for all four APMV-2 strains 
were more than 168 h and zero, respectively. These results indicated that APMV-2 strains are 
avirulent in chickens, similar to lentogenic NDV strains.  
 
APMV-2  antiserum 
            













        strain Yucaipa 
Yucaipa 160 40 
Bangor 20 10 
England 40 40 
Kenya 40 40 
 
strain Bangor 
Yucaipa 20 10 
Bangor 80 40 
England 40 20 
Kenya 40 20 
 
strain England 
Yucaipa 40 20 
Bangor 40 20 
England 160 80 
Kenya 160 40 
 
strain Kenya 
Yucaipa 80 20 
Bangor 40 20 
England 320 40 





3.5.4 Determination of the complete genome sequences of APMV-2 strains Yucaipa, 
Bangor, England and Kenya. We determined the complete genome sequences of APMV-2 
strains Yucaipa, Bangor, England and Kenya. Initially the complete genome sequence of strain 
Yucaipa was determined using three strategies; using consensus primers designed from the 
existing sequences of other paramyxoviruses, secondly, using primers with gene-start and gene-
end sequences and finally by primer walking method as described in materials and methods 
section. A number of the initial cDNAs in this analysis was synthesized using primers derived 
from the published sequence of APMV-2 strain Yucaipa (Table 1). Every nt in the complete 
sequence was confirmed in uncloned cDNA, indicating that it is a consensus sequence.  The 
genome of strain England is similar in length (14904 nt) to that of strain Yucaipa. However, the 
genome lengths of strains Bangor (15024 nt) and Kenya (14916 nt) are slightly larger than that of 
strain Yucaipa (14904 nt). The nt lengths of the genome of all four strains are multiple of six. 
Thus all four strains conform to the rule of six, which is a characteristic of the genome of all 
members of subfamily Paramyxovirinae (Kolakofsky et al., 1998). All three APMV-2 strains 





The complete genome of strain Bangor has 70.4% nt and 75.3% aggregated aa sequence 
identities with those of strain Yucaipa. The strains England and Kenya are very closely related to 
strain Yucaipa with a nt sequence identity of 94.5% and 88%, respectively, and an aggregate aa 
sequence identity of 96.1% and 92.4%, respectively. However, both the strains have 69.4% and 
70.8% nt and 76.15% and 76.3% aggregate aa sequence identities, respectively, with those of 




strain Bangor is somewhat distinct. This is consistent with the finding noted before that strain 
Bangor is distinct antigenically.  
The 3‟ leader sequences of APMV-2 strains consist of 55 nt which is conserved among 
almost all the members of the subfamily Paramyxovirinae. The nt sequences of the leader region 
of strains Bangor and Yucaipa shows differences at 9 out of 55 nt positions, while those of 
strains England and Kenya are 100% identical to strain Yucaipa (Fig. 3.2A). The lengths of 
trailer regions of APMV-2 strains England and Kenya are 154 nt each, same as strain Yucaipa. 
But the length of trailer region of strain Bangor is 173 nt (Fig. 3.2B). The sequence of trailer 
region of strains England and Kenya are 100% identical to strain Yucaipa, but the sequence of 







































Fig. 3.2. The nucleotide (nt) sequence alignment of the leader (A) and 5‟ 60 nt of trailer (B) 
regions of the indicated APMV-2 strains. Dots indicate identity with strain Yucaipa. Sequences 
are in negative-sense. Numbers indicate nt position. 
 
The proposed gene-start (GS) and gene-end (GE) signal sequences are highly conserved 
among APMV-2 strains (Table 3.3). In general, the conserved GS and GE sequences of all the 




Bangor, the GS and GE sequences show single nt variations compared to the other three strains 
(Table 3.3).  
The intergenic sequences (IGS) of APMV-2 strains vary in length from 3 to 23 nt and are 
mostly conserved between genes N, P, M and F (Table 3.3). The IGS sequences of strain 
England are 100% identical in length and sequence to strain Yucaipa. The IGS sequences of 
strain Kenya are also 100% identical in length and sequence to strain Yucaipa except between 
HN and L genes. However, the IGS sequences of strain Bangor show less than 50% nt identity 
with that of strain Yucaipa. In particular, the IGS between F and HN in strain Bangor is only 4 nt 
in length compared to 9 nt in length in the other three strains and the IGS between HN and L is 8 
nt in length in strains Bangor and Kenya compared to 3 nt in length in the other two strains.  
 
The nucleocapsid protein (N) gene. The N gene of APMV-2 strains Yucaipa, Bangor, 
England and Kenya is 1547 nt in length and encodes a N protein of 457 aa (Table 3.3). The N 
protein of strains Bangor, England and Kenya has 90.4%, 99.3% and 94.5% aa sequence identity, 
respectively, with that of strain Yucaipa (Table 3.4).  An amino acid sequence motif that is 
highly conserved in the N proteins of members of subfamily Paramyxovirinae and known to be 
involved in N–N self assembly, F-X4-Y-X3-ɸ-S-ɸ-A-M-G, where X represents any amino acid 
residue and ɸ represents an aromatic amino acid residue (Morgan, 1991) is present within the 














Table 3.3 APMV-2 Molecular features of genes and their deduced protein products. Differences 











































 Bangor  GGGGGCGACA 75 1374 77 TTAAGAAAAAA 7 457 
 England  GGGGGCGACA 75 1374 77 TTAAGAAAAAA 7 457 
 Kenya  GGGGGCGACA 75 1374 77 TTAAGAAAAAA 7 457 
          
P Yucaipa  GGGGGCGAAG 61 1200 97 TTAACAAAAAA 7 399 
 Bangor  GGGGGCGAAT 61 1200 97 TAAGAAAAAAA 7 399 
 England  GGGGGCGAAG 61 1200 97 TTAACAAAAAA 7 399 
 Kenya  GGGGGCGAAG 61 1200 97 TTAACAAAAAA 7 399 



















 Bangor  GGGGGCGAAT 61 699 599 TAAGAAAAAAA - 232 
 England  GGGGGCGAAG 61 699 599 TTAACAAAAAA - 232 
 Kenya  GGGGGCGAAG 61 699 599 TTAACAAAAAA - 232 
          
P/W Yucaipa  GGGGGCGAAG 61 624 675 TTAACAAAAAA - 207 
 Bangor  GGGGGCGAAT 61 462 837 TAAGAAAAAAA - 153 
 England  GGGGGCGAAG 61 624 675 TTAACAAAAAA - 207 
 Kenya  GGGGGCGAAG 61 624 675 TTAACAAAAAA - 207 



















 Bangor  GGGGGCGAAT 38 1110 135 TTTAGAAAAAA 23 369 
 England  GGGGGCGAAG 32 1110 117 TTAAGAAAAAA 23 369 
 Kenya  GGGGGCGAAG 32 1110 117 TTAAGAAAAAA 23 369 



















 Bangor  GGGGGCGAAA 20 1635 84 TTAAGAAAAAA 4 544 
 England  GGGGGCGACA 44 1611 31 TTAAGAAAAAA 9 536 
 Kenya  GGGGGCGACA 44 1611 31 TTAAGAAAAAA 9 536 



















 Bangor  GGGGGCGAAA 60 1752 61 TTAATAAAAAA 8 583 
 England  GGGGGCGACA 66 1743 69 TTAAGAAAAAA 3 580 
 Kenya  GGGGGCGACA 72 1749 64 TTAATAAAAAA 8 582 



















 Bangor  GGGGGCGAAT 11 6729 102 TTAAGAAAAAA - 2242 
 England  GGGGGCGAAT 11 6729 73 TTAAGAAAAAA - 2242 





The phosphoprotein (P) gene and P/V/W editing. The P gene of APMV-2 strains 
Yucaipa, Bangor, England and Kenya is 1379 nt in length and encodes a P protein of 399 aa 
(Table 3.3). The P protein of strains Bangor, England and Kenya has 55.8%, 87.7% and 99.5% 
aa sequence identity, respectively, with that of strain Yucaipa (Table 3.4). The P gene of strains 
Bangor, England and Kenya contain a putative P gene editing site (3‟-UUUUUCCCC (negative-
sense), located at nt position 2092–2100 in the viral RNA genome. The addition of a single G 
residue to the editing site would yield a predicted V protein and the addition of 2 G residues 
would yield a predicted W protein, as is the case with NDV (Steward et al., 1993). The addition 
of a single G residue into the encoded mRNA would produce a V mRNA encoding a 232 aa V 
protein. For all four strains, the V protein domain contains the conserved cysteine rich motif that 
is characteristic of most members of subfamily Paramyxovirinae (Fig. 3.3). The addition of two 
G residues into the encoded mRNA of the P gene editing site would produce a W mRNA 
encoding a W protein. The W protein of strains England and Kenya is 207 aa, similar to strain 
Yucaipa, while that of strain Bangor is only 153 aa (Table 3.3).  
 










APMV-2 England          181....................................................232 






Fig. 3.3 Amino acid sequence alignment of the C-terminal domain of the V proteins of the 
indicated APMV-2 strains. Conserved cysteine (C) residues are underlined; dots indicate identity 
with strain Yucaipa. Numbers indicate the amino acid position.  
 
The matrix protein (M) gene. The M gene of APMV-2 strains England and Kenya is 
1280 nt in length similar to that of strain Yucaipa. But the M gene of strain Bangor is 1304 nt in 




untranslated regions.  The M gene of all four strains encodes a M protein of 369 aa The M 
protein of strains Bangor, England and Kenya has 85.1%, 99.7% and 98.4% aa sequence identity, 










Table 3.4. The amino acid percentage identity between APMV-2 strains Yucaipa, Bangor, 
England  
and Kenya.  
 
The fusion protein (F) gene. The F gene of APMV-2 strains Yucaipa, Bangor, England 
and Kenya is 1707 nt in length and encodes a F protein of 536 aa (Table 3.3). The F protein of 
strains Bangor, England and Kenya has 79.1%, 99.8% and 98.1% aa sequence identity, 
respectively, with that of strain Yucaipa (Table 3.4). In APMV-1, the cleavage sequence of the F 
protein has been shown to be a critical factor for viral entry and pathogenesis. For APMV-2 
strains England, Kenya and the prototype strain Yucaipa, the aa sequences spanning the F protein 
















 Bangor England Kenya Bangor England Kenya Bangor England Kenya 
Yucaipa 90.4 99.3 94.5 55.8 87.7 99.5 85.1 99.7 98.4 
Bangor  89.9 89.7  60.8 55.3  84.8 85.1 
England   94.1   87.2   98.1 

















 Bangor England Kenya Bangor England Kenya Bangor England Kenya 
Yucaipa 79.1 99.8 98.1 75 96 76.2 66.5 94.2 87.8 
Bangor  78.9 77.6  75.2 85.1  67.4 68.2 
England   97.9   76.4   86.1 




contain dibasic aa residues. Whereas, in strain Bangor, the cleavage site contains only one basic 
aa residue (TLPSAR↓F). A similar difference in the number of basic amino acids at cleavage site 
between strains of same serotype has been reported in APMV-6 (Xiao et al., 2010). However, all 
the APMV-2 strains contain phenylalanine residue at the F1 amino terminal end as seen in 
virulent APMV-1 strains (Fig. 3.4) (Lamb and Parks, 2007). All the APMV-2 strains sequenced 
to date contain one or two basic aa residues at the F protein cleavage site and a phenylalanine at 
the F1 N-terminal end but do not require exogenous protease supplementation for growth in cell 
cultures.  
 
APMV-2 (Yucaipa)      
93 
DKPASR  F100 
APMV-2 (Bangor)       
101
TLPSAR  F108 
APMV-2 (England)      
93 
DKPASR  F100 
APMV-2 (Kenya)        
93 
DKPASR  F100 
APMV-1(Avirulent)     
111
GGRQGR  L117  
APMV-1(Virulent)      
111
GRRQKR  F117 
APMV-3(Netherland)    
101
ARPRGR  L107 
APMV-3(Wisconsin)     
96 
PRPSGR  L102 
APMV-4                
115
ADIQPR  F121 
APMV-5                
104
GKRKKR  F110 
APMV-6(Hong Kong)     
113
PAPEPR  L119 
APMV-6(IT4524-2)      
103
SIREPR  L109 
APMV-7                
101
TLPSSR  F107 
APMV-8                
98 
TYPQTR  L104 
APMV-9                
105
IREGRI  F111 
 
Fig. 3.4 Alignment of the F protein cleavage site sequence of APMV-2 strains with those of 
other APMVs. Basic amino acids (R=arginine and K=lysine) are underlined and in bold. 





The hemagglutinin-neuraminidase (HN) gene. The HN gene of APMV-2 strain 
England is 1899 nt long, similar to strain Yucaipa, while the length of HN gene of strains Bangor 
and Kenya are 1894 nt and 1906 nt, respectively. The lengths of HN protein of strains Yucaipa 
and England are 580 aa, while those of strains Bangor and Kenya are 583 and 582 aa, 
respectively (Table 3.3). The HN protein of strains Bangor, England and Kenya has 75%, 96% 
and 76.2% aa sequence identity, respectively, with that of strain Yucaipa (Table 3.4). In addition, 
all the four strains have the hexapeptide (NRKSCS) known to form part of the sialic acid binding 
site (Mirza et al., 1994).   
The large polymerase protein (L) gene. The L gene of APMV-2 strains England and 
Kenya is 6834 nt long same as that of strain Yucaipa. The L gene of strain Bangor is 6863 in 
length. The L genes of all four strains encode a L protein of 2242 aa (Table 3.3). The L protein 
of strains Bangor, England and Kenya has 66.5%, 94.2% and 87.8% aa sequence identity, 
respectively, with that of strain Yucaipa (Table 3.4). In addition, all four strains have the 
conserved motif GDNQ in the L protein domain III as seen in all non-segmented negative strand 
RNA viruses and known to be involved in L protein transcriptional activity (Schnell and 
Conzelmann, 1995).   
 
3.5.5 Phylogenetic analysis. The phylogenetic tree was generated from alignments of the 
complete nt sequences of the genome of APMV-2 strains Bangor, England and Kenya with those 
of the representative paramyxoviruses (Fig. 3.5). The resulting phylogenic tree shows APMV-2 
strains clustering together on a branch that is distinct from other paramyxoviruses. Also, strains 






Fig. 3.5 Phylogenetic tree of representative members of the family Paramyxoviridae. The 
phylogenetic tree of representative members of the family Paramyxoviridae was constructed 
with the complete genome sequences and using MEGA 4.1, Molecular Evolutionary Genetics 





Avian paramyxoviruses are classified into nine serotypes based on their serological 
relationships in HI and NI tests (Alexander, 2003). Among these serotypes, APMV-1 causes 
severe disease in poultry; hence, a great deal of information is available on the antigenic and 
genetic relationships among APMV-1 strains isolated from different parts of the world 
(Alexander, 1988). Recently we and others have reported complete genome sequences for 
representative strains of APMV-2 to -9 (Subbiah et al., 2008; Kumar et al., 2008; Nayak et al., 
2008; Samuel et al., 2010; Chang et al., 2001; Xiao et al., 2009; Paldurai et al., 2009; Samuel et 
al., 2009). However, very little information is available about the antigenic and genetic 
relationships among the strains of the serotypes 2 through 9 (Alexander, 2003). In this study we 
have determined the antigenic and genetic relations among APMV-2 strains Yucaipa, Bangor, 
England and Kenya isolated from a chicken, finch, chicken and gadwell, respectively. 
Furthermore, these strains were isolated from different parts of the world and in different years. 
Therefore, it was interesting to know the antigenic and genetic variations among these strains. 
The antigenic relationships among these four strains were evaluated using cross-HI and cross-
serum microneutralization assays. This information will have implications for studies in 
pathogenesis, epidemiology and for the development of vaccines against APMV-2.  
To evaluate the antigenic relationship among the four APMV-2 strains described in the 
present study, we raised chicken antisera against strains Yucaipa, Bangor, England and Kenya 
individually by respiratory infection mimicking a natural route of infection. Since serological 
responses tend to broaden over time, and with repeated antigenic exposure, we limited the 
immunization to a single infection and collected serum samples at an early time point (14 dpi). 




fold higher against homologous strain Yucaipa than against strains Bangor, England and Kenya, 
respectively. The antisera specific for strains Bangor, England and Kenya showed 4-, 4- and 8-
fold higher against their homologous viruses than against prototype strain Yucaipa. The 
antiserum specific for strain Bangor showed 2-fold higher HI titer against strain Bangor than 
against strains England and Kenya. The antiserum specific for strain England showed 4-fold 
higher titer against strains England and Kenya than against strain Bangor. The antiserum specific 
for strain Kenya showed 16- and 2- fold higher titers against homologous strain Kenya than 
against strains Bangor and England, respectively. Our cross-HI results suggested that all four 
APMV-2 strains represent a single serotype but two antigenic subgroups.  
Our results from the microneutralization tests in cell culture showed that the antisera 
cross-neutralized the heterologous strain, but the neutralization titers were 2- to 4-fold higher 
against the homologous strain than against the heterologous strains. These results again 
suggested an antigenic dimorphism that would be consistent with the existence of two antigenic 
subgroups within APMV-2, with strains Yucaipa, England and Kenya belonging to one antigenic 
subgroup and with strain Bangor belonging to the second antigenic subgroup, as seen with 
APMV-3 and -6 strains (Kumar et al., 2010; Xiao et al., 2010). It was previously suggested that 
strain Bangor be classified as a separate serotype or as a subtype of serotype 2 (McFerran et al., 
1974) based on distinct differences in neuraminidase activities (Alexander et al., 1974) and cross 
serum neutralization tests between strains Bangor and Yucaipa. Our data also suggests the 
classification of strain Bangor as a separate subgroup within serotype 2. In this respect, it will be 





The genome lengths of strains Yucaipa, Bangor, England and Kenya are 14904, 15024, 
14904 and 14916 nt, respectively. Among APMV-1 (NDV) strains, there are three genome sizes: 
(1) 15,186 nt in early (>1930s) isolated strains, 2) 15,192 nt in late (>1960s) isolated strains (due 
to a six nt insertion in the upstream of the N gene), and (3) 15,198 nt (12 nt insertion in the P 
gene ORF) (Czeglédi et al., 2006). These different genome sizes of NDV strains did not relate to 
the viral virulence, but seem to be related to the time (year) of virus isolation with the genomes 
becoming progressively longer (Miller et al., 2009; Czeglédi et al., 2006). However, in APMV-
2, the genome length does not seem to be decided by the year of isolation but rather by the host 
species. The strains Yucaipa and England were both isolated from chicken and have the same 
genome length (14904 nt). Despite the difference in the genome length, all four strains follow the 
“rule of six” indicating that this rule is a requirement for virus replication and survival.   
The genome sequence of strain Bangor showed 70.4% nt and 75.3% aggregated aa 
sequence identities with the previously reported prototype strain Yucaipa. The strains England 
and Kenya are closely related to strain Yucaipa, with a nt sequence identity of 94.5% and 88%, 
respectively, and an aggregate aa sequence identity of 96.1% and 92.4%, respectively. However, 
both these strains show 69.4% and 70.8% nt, respectively, and 76.1% and 76.8% aggregate aa 
sequence identity, respectively, with strain Bangor. The strains England and Kenya show 86.1% 
nt and 89.9% aggregated aa sequence identities between each other. Our results indicate that 
strains Yucaipa, England and Kenya are closely related genetically, but strain Bangor is 
somewhat distinct. This is consistent with the finding noted before that strain Bangor is distinct 
antigenically.  
Comparison of aa sequence relatedness of cognate proteins between the APMV-2 strains 




were more divergent (55.8 and 66.5% aa identity, respectively) than other strains. The extent of 
variability in the APMV-2 P proteins is similar to that observed among APMV-6 strains (Xiao et 
al., 2010) but in contrast to that of the P proteins of the two subgroups of HMPV and HRSV, 
which are more highly conserved (85 and 90% aa identity, respectively) (Biacchesi et al., 2003). 
The V protein of strain Bangor showed only 57% aa identity with that of prototype strain 
Yucaipa, while the V protein of strains England and Kenya showed 99.1% and 100% aa identity, 
respectively, with that of strain Yucaipa. In addition, it is interesting to note that the W protein of 
strain Bangor was smaller in length, 153 aa compared to a length of 207 aa of the other three 
strains. Similar difference in W protein size between strains of same serotype has been reported 
in APMV-8 (Paldurai et al., 2009). Since the role of W protein is not known, the functional 
significance of the W protein size difference remains to be studied.   It is also interesting to find 
that the F and HN proteins of strain Bangor exhibited more divergence (79.1% and 75% aa 
identity, respectively) with those of the prototype strain Yucaipa while the F and G proteins of 
the HMPV subgroups show 95% and 73% aa identity, respectively, and the HRSV subgroups 
show 89% and 37% aa identity, respectively (Biacchesi et al., 2003).   
Another difference between strain Bangor and the other three strains was observed in the 
fusion protein cleavage site which plays a major role in NDV pathogenesis (Lamb and Parks, 
2007). Virulent NDV strains have a multiple basic aa cleavage site R-X-K/R-R↓F, which is 
cleaved intracellularly by ubiquitous cellular furin-like proteases and a phenylalanine (F) residue 
at the beginning of the F1 subunit, which also may play a role in facilitating cleavage (Morrison 
et al., 1993). The avirulent NDV strains have one or a few basic residues at the cleavage site and 
do not conform to the furin motif and have a leucine (L) residue at the first position of F1 




cleavage site sequences of some serotypes are not necessarily predictive of the protease 
activation phenotype (Samuel et al., 2010). The putative F protein cleavage site (DKPASR↓F) of 
the strains England and Kenya resembled that of prototype strain Yucaipa and contained dibasic 
residues and a phenylalanine residue at the F1 terminal end, while that of strain Bangor 
(TLPSAR↓F) contained only one basic amino acid. However, none of the sites conform to the 
furin cleavage site. Each of these strains replicated in a trypsin-independent manner in both the 
cell lines that we tested and the addition of trypsin did not substantially increase virus 
replication, similar to the prototype strain Yucaipa (Subbiah et al., 2008). On the basis of 
cleavage site, it will be difficult to predict the virulence of these strains unlike in the case of 
APMV-1 strains. Our results of MDT in chicken eggs and ICPI in day-old chicks provided 
evidence of an avirulent phenotype for each of these strains in chickens.  
In conclusion, the complete genome sequences were determined for APMV-2 strains 
Yucaipa, Bangor, England and Kenya. Comparison of the nt and predicted protein aa sequences 
among four APMV-2 strains showed the existence of divergence between strains Yucaipa, 
England, Kenya and Bangor, suggesting the subgrouping of the  APMV-2 strains as reported 
with APMV-3 and -6 strains. This grouping based on sequence relatedness and phylogenetic tree 
was also consistent with the antigenic analysis. This indicated that APMV-2 strains represent two 
APMV-2 subgroups and we propose that the prototype strain Yucaipa and strains England and 
Kenya represent one subgroup while strain Bangor represents a second subgroup. It will be 
interesting in future to look at the antigenic and genetic analyses of other APMV-2 strains 









Pathogenesis of two strains of Avian Paramyxovirus serotype 2, Yucaipa and Bangor, in 
chickens and turkeys. 
 
4.2 Abstract 
Nine serological types of avian paramyxovirus (APMV) have been recognized. 
Newcastle disease virus (NDV) belongs to APMV-1 and is the most extensively 
characterized virus; while relatively little information is available about the other APMV 
serotypes. In the present study, we examined the pathogenicity of two strains of APMV-2, 
Yucaipa and Bangor, in 9-day-old embryonated chicken eggs, 1-day-old Specific Pathogen Free 
(SPF) chicks, and 4-week-old SPF chickens and turkeys. The mean death time (MDT) in 9-day-
old embryonated chicken eggs was more than 168 h for both strains and their Intra 
Cerebral Pathogenicity Index (ICPI) was zero, indicating that these viruses are nonpathogenic in 
chickens. When inoculated intracerebrally in 1-day old chicks, neither of the strains caused 
disease nor replicated detectably in the brain. This suggests that the zero ICPI value of APMV-2 
reflects the inability of the virus to grow in neural cells. Groups of twelve 4-week-old SPF 
chickens and turkeys were inoculated oculonasally with either strain, and three birds per group 
were euthanized on days 2, 4, 6, and 14 post-inoculation for analysis. There were no overt 
clinical signs of illnesses, although all birds seroconverted by day 6. Virus isolation and 
quantification was performed from a wide variety of tissue samples as well as from oral and 




isolated predominantly from the respiratory and alimentary tracts. Immunohistochemistry also 
showed the presence of large amount of viral antigens in epithelial linings of respiratory and 
alimentary tracts. There also was evidence of systemic spread even though the cleavage site of 
the viral fusion glycoprotein does not contain the canonical furin protease cleavage site.  
 
4.3 Introduction 
The family Paramyxoviridae includes a large group of viruses isolated from a wide 
variety of animal species. Many members of this family are well known human (measles, mumps 
and respiratory syncytial viruses) and animal (Newcastle disease virus [NDV], canine distemper 
and rinderpest viruses) pathogens, while the disease potential of other members is not known. 
The viruses belonging to family Paramyxoviridae are pleomorphic and enveloped with a non-
segmented negative-sense RNA genome. This family is divided into two subfamilies, 
Paramyxovirinae and Pneumovirinae, based on their structure, genome organization, and 
sequence relatedness (Lamb et al.,  2005). The subfamily Paramyxovirinae comprises five 
genera- Respirovirus, Rubulavirus, Morbillivirus, Henipavirus and Avulavirus, while the 
subfamily Pneumovirinae contains two genera, Pneumovirus and Metapneumovirus (Mayo, 
2002).  
All Paramyxoviruses that have been isolated to date from avian species segregate into 
genus Avulavirus, representing the avian paramyxoviruses (APMV), and genus 
Metapneumovirus, representing the avian pneumoviruses.  The APMV comprising genus 
Avulavirus have been organized into nine serotypes (APMV 1 through 9) based on 
hemagglutination inhibition (HI) and neuraminidase inhibition (NI) assays (Alexander, 2003).  




the severity of disease caused by virulent NDV strains in chickens. The complete genome 
sequences and the molecular determinants of virulence have been determined for representative 
NDV strains (Krishnamurthy & Samal, 1998; de Leeuw & Peeters, 1999; Panda et al., 2004; 
Huang et al., 2004; Rout & Samal, 2008). As a first step in characterizing other APMV 
serotypes, complete genome sequences of APMV serotypes 2 to 9 were recently determined, 
expanding our knowledge about these viruses (Chang et al., 2001; Subbiah et al., 2008; Kumar 
et al., 2008; Nayak et al., 2008; Jeon et al., 2008; Samuel et al., 2009; Paldurai et al., 2009; Xiao 
et al.,  2009; Samuel et al., 2010).  
NDV (APMV-1) strains segregate into three pathotypes: highly virulent (velogenic) 
strains that cause severe respiratory and neurological diseases in chickens; moderately virulent 
(mesogenic) strains that cause milder disease, and nonpathogenic (lentogenic) strains that cause 
inapparent infection and can serve as live vaccines against NDV disease. NDV remains the most 
important poultry pathogen. In contrast, little is known about the disease potential of APMV-2 to 
APMV-9. APMV-2 infections have been associated with severe respiratory disease and drop in 
egg production in turkeys (Bankowski et al., 1981; Lipkind et al., 1979). APMV-3 infections 
have also been found to cause stunted growth in young chickens (Alexander and Collins, 1982). 
APMV-6 and -7 were reported to cause a mild respiratory disease in turkeys (Alexander, 1997, 
Shortridge et al., 1980; Saif et al., 1997). APMV-5 caused severe mortality in budgerigars 
(Nerome et al., 1978). APMV-4, -8, and -9, isolated from ducks, waterfowl, and other wild birds 
did not produce any clinical signs of viral infection in chickens (Alexander, 1982; Gough & 
Alexander, 1984; Stallknecht et al.,  1991; Maldonado et al.,  1995; Capua et al.,  2004). 
Recently, experimental infection of 1-day-old chicks with APMV-2, -4 and -6 showed viral 




APMV-2 appears to be circulating widely and has been isolated from a wide variety of 
birds, and especially from chickens and turkeys. APMV-2 infections have been reported in 
chickens, turkeys, racing pigeons and feral birds across the globe (Alexander, 1982; Asahara et 
al.,  1973; Collings et al.,  1975; Goodman et al.,  1988; Lang et al.,  1975; Lipkind et al.,  1979; 
Lipkind et al.,  1981; Lipkind et al.,  1982; Mbugua et al.,  1985; Nymadawa et al.,  1977; 
Shihmanter et al.,  1997; Weisman et al.,  1984). APMV-2 strains are endemic among 
passeriformes and psittacines in Senegal and on the island of Hiddensee, GDR, in the Balt ic Sea 
(Fleury & Alexander, 1979, Nymadawa et al., 1977). The prevalence of APMV-2 antibodies has 
been studied in different avian species including commercial poultry (Ley et al., 2000; Zhang et 
al., 2007; Warke et al., 2008). APMV-2 strains have been isolated from chickens, broilers and 
layers in USA, Canada, Russia, Japan, Israel, India, Saudi Arabia, Great Britain and Costa Rica, 
and from turkeys in the USA, Canada, Israel, France and Italy. Serological surveys of poultry in 
the USA indicated that this virus was widespread (Bankowski et al., 1968, Bradshaw & Jensen, 
1979). APMV-2 infections affected the hatchability and poult yield in turkeys (Bankowski et al., 
1981). However, more serious disease has been reported during secondary infections (Lang et 
al., 1975). Virus isolation and the presence of antibodies have also revealed APMV-2 infections 
in turkey flocks without causing any clinical disease (Bradshaw & Jensen, 1979). APMV-2 
isolated from commercial layer farms and from broiler breeder farms in Scotland was suspected 
to be the cause for drop in egg production (Wood et al., 2008). Experimental infection of 
APMV-2 in chicken by intramuscular and intratracheal route failed to produce any detectable 
respiratory illness (Bankowski & Corstvet, 1961). Similar results were observed in turkeys 




Currently, it is not known whether there is any variation in pathogenicity among APMV-
2 strains. The purpose of this study was to evaluate the pathogenicity of APMV-2 strains 
Yucaipa and Bangor, both of which were completely sequenced recently (Subbiah et al., 2008 
and our unpublished data). APMV-2 strain Yucaipa was first isolated in 1956 from a diseased 
chicken (Bankowski et al., 1960) and is considered the prototype strain of the APMV-2. APMV-
2 strain Bangor was isolated in 1973 from a finch by routine examination during quarantine 
(McFerran, 1973). Initially these two viruses were considered as separate antigenic groups due to 
their four-fold difference in the serum cross neutralization test, but they are now grouped 
together as two different strains of APMV-2 (McFerran, 1974). In this study, we studied 
infection of APMV-2 strains Yucaipa and Bangor in 9-day-old embryonated chicken eggs, 1-
day-old chicks, and 4-week-old chickens and turkeys in order to investigate their tropism and 
pathogenicity.  The 1-day-old chicks were infected intracerebrally to evaluate the potential for 
neurotropism. The older birds were infected by the oculonasal route and the viral tropism and 
replication efficiency were evaluated by quantitative virology and immunohistochemistry of a 
wide range of possible target organs.  
 
4.4 Materials and Methods 
 
4.4.1 Viruses and cells. APMV-2 strains Yucaipa (APMV-2/chicken/USA(Ca)/Yucaipa/1956) 
and Bangor (APMV-2/finch/N.Ireland/Bangor/1973) were obtained from National Veterinary 
Services Laboratory, Ames, Iowa. APMV-1 lentogenic strain LaSota and mesogenic strain 
Beaudette C (BC) were used for comparison purposes in pathogenicity tests and for studying 




Bio Safety Level (BSL)-2 facility and the latter study was performed in our BSL-2+ animal 
facility. The viruses were grown in 9-day-old specific pathogen free (SPF) embryonated chicken 
eggs via allantoic route of inoculation. The allantoic fluids from infected embryonated eggs were 
collected 96 h post-inoculation and titer of the virus was determined by hemagglutination (HA) 
assay with 0.5% chicken RBC. The virus
 
titers in the tissue samples were determined by 50% 
tissue culture infectivity dose (TCID50) assay in DF1 cells (chicken embryo fibroblast cell line), 
calculated by the method of Reed and Muench (Reed and Muench, 1938).  
 





) dilutions of fresh infective allantoic fluid in sterile phosphate-buffered 
saline (PBS) were made and 0.1 ml of each dilution was inoculated into the allantoic cavities of 
five 9-day-old embryonated SPF chicken eggs, which were then incubated at 37°C. Each egg 
was examined three times daily for 7 days, and the times of embryo deaths were recorded. The 
minimum lethal dose is the highest virus dilution that caused death of all the embryos. MDT is 
the mean time in hours for the minimum lethal dose to kill all inoculated embryos. The MDT has 
been used to characterize the NDV pathotypes as follows: velogenic (less than 60 h), mesogenic 
(60 to 90 h), and lentogenic (more than 90 h) (Alexander, 1989).  
 
4.4.3 Intracerebral Pathogenicity Index (ICPI) in 1-day-old chicks. Briefly, 0.05 ml of 1/10 
dilution of fresh infective allantoic fluid (2
8 
HA units) of each virus was inoculated into groups 
of ten 1-day-old SPF chicks via intracerebral route. The birds were observed for clinical 
symptoms and mortality every 8 h for a period of 8 days. At each observation, the birds were 




observation over the 8-day period. Highly virulent NDV (velogenic) viruses give values 
approaching 2 and avirulent NDV (lentogenic) viruses give values close to 0 (Alexander, 1989).  
 
4.4.4 Replication and viral growth kinetics in brain tissue of 1-day-old chicks. To compare 
the replication of APMV-2 strains Yucaipa and Bangor in chick
 
brains, groups of twelve 1-day-
old SPF chicks were inoculated with 0.05 ml of a 1/10 dilution of 2
8 
HA units of fresh infected 
allantoic fluid via the intracerebral route.
 
APMV-1 strain BC was included for comparison 
purposes. Brain tissue samples were collected by sacrificing three birds from each group on 1, 2, 
3 and 4 days post inoculation (dpi), or when any birds died of infection. The samples were snap-
frozen on dry
 
ice and homogenized. The virus
 
titers in the tissue samples were determined by 
50% tissue culture infectivity dose (TCID50) in DF1 cells (chicken embryo fibroblast cell line) by 
Reed and Muench method (Reed and Muench, 1938).  
 
4.4.5 Pathogenicity assessment in chickens and turkeys. Two groups of twelve 4-week-old 
SPF chickens (Charles River, Maryland, USA) were housed in negative pressure isolators in our 
BSL-2 facility and were provided with food and water ad libitum.  Birds in group one were 
inoculated with a total volume of 0.2 ml of 2
8
 HA units of APMV-2 strain Yucaipa contained in 
freshly-harvested infected-egg allantoic fluid via the intranasal and intraocular routes, and the 
birds in group two were inoculated with the same dose of APMV-2 strain Bangor by the same 
routes. The inoculations were performed on separate days to avoid cross infection between the 
groups. Similarly two groups of twelve 4-week-old Midget White turkeys (McMurray Hatchery, 
Iowa, USA) were infected with the two strains of APMV-2 using the same dose and the same 




euthanized on 2, 4 and 6 dpi by placing them directly inside a CO2 chamber. The birds were 
swabbed orally and cloacally just before euthanasia. The following tissue samples were collected 
on dry ice, both for immunohistochemistry (IHC) and for virus isolation: eyelid, trachea, lung, 
liver, spleen, brain, colon, caecal tonsil, bursa and kidney. Serum samples were also collected. 
On day 14, the three remaining birds from each group were euthanized and serum samples were 
collected. Seroconversion was evaluated by hemagglutination inhibition (HI) assay (Alexander, 
1996).   
 
4.4.6 Virus detection and quantification from tissue samples and swabs. Infectious virus was 
detected by inoculating homogenized tissue samples in 9-day-old embryonated SPF chicken eggs 
and testing for HA activity of the infected allantoic fluids 4 dpi. All HA positive samples were 
considered as virus-positive tissue samples. The virus
 
titers in the HA-positive tissue samples 
were determined by TCID50 method in DF1 cells (Reed and Muench, 1938). 
The oral and cloacal swabs were collected in 1 ml of PBS containing antibiotics. The 
swab containing tubes were centrifuged at 1000x g for 20 min, and the supernatant was removed 
for virus detection. Infectious virus was detected by infecting this supernatant into 9-day-old 
embryonated SPF chicken eggs. Positive samples were identified by HA activity of the allantoic 
fluid harvested from eggs 4 dpi. 
 
4.4.7 Immunohistochemistry. Sections of all the frozen tissue samples were prepared at 
Histoserve, Inc. (Maryland, USA). The sections were immunostained to detect viral nucleocapsid 
(N) protein using the following protocol.  Briefly, the frozen sections were thawed and 




for 15 min at -80
o
C and then washed three times with 2% BSA in PBS and blocked with the 
same for 1 h at room temperature. The sections were then incubated with a 1:500 dilution of the 
primary antibody (hyperimmune sera raised against the N protein of APMV-2 strain Yucaipa in 
rabbit) in PBS overnight in a humidified chamber. After three washes with 2% BSA in PBS, 
sections were incubated with the secondary antibody (FITC conjugated goat anti-rabbit antibody) 
for 30 min. After a further wash cycle, the sections were mounted with glycerol and viewed 
under an immunofluorescence microscope.  
 
4.4.8 Preparation of hyperimmune antiserum against the viral N protein in a rabbit. 
APMV-2 strain Yucaipa virions were purified on a sucrose gradient and the virion proteins were 
separated on a 10% SDS-Polyacrylamide gel and negatively stained using E-Zinc TM reversible 
stain kit (Pierce, Rockford, IL, USA). The N protein band was excised from the gel and 
destained with Tris-glycine buffer pH 8. The excised gel band was minced in a clean pestle and 
mixed with elution buffer (50 mM Tris-HCl buffer pH 8, 150 mM NaCl, 0.5 mM EDTA, 5 mM 
DTT and 0.1% SDS) and transferred to the upper chamber of a Nanosep centrifugal device (Pall 
Life Sciences, Ann Arbor, MI, USA). After centrifugation two times, the eluted protein in the 
supernatant was quantified and 0.2 mg of protein was mixed in complete Freund's adjuvant and 
injected subcutaneously into a rabbit. After two weeks a booster immunization was given with 
0.2 mg of protein in incomplete Freund‟s adjuvant and 2 weeks later the hyperimmune sera was 
collected. This serum was tested by western blot and was found to recognize specifically the N 








4.5.1 The pathogenicity index tests. The pathogenicity of APMV-2 strains Yucaipa and Bangor 
was evaluated by MDT in 9-day-old embryonated SPF chicken eggs and ICPI in 1-day-old 
chicks. The lentogenic NDV strain LaSota was included in the pathogenicity test for comparison. 
The MDT for both of the APMV-2 strains was more than 168 h. The ICPI value was zero for 
both the strains. The MDT and ICPI values of NDV strain LaSota were 110 h and zero, 
respectively, consistent with a lentogenic virus. These results indicate that APMV-2 strains 
Yucaipa and Bangor are probably nonpathogenic to chickens, similar to lentogenic NDV strains.  
 
4.5.2 Virus growth in the chick brain. The ability of the APMV-2 strains Yucaipa and Bangor 
to grow in the brains of 1-day-old chicks was evaluated in parallel with the mesogenic 
neurotropic NDV strain BC. This study was performed to determine whether the zero ICPI value 
of APMV-2 strains was due to the inability of the virus to grow intracerebrally or if there was 
virus multiplication without a high degree of cell destruction.  
 Virus replication was evaluated by inoculating 0.05 ml of a 1:10 dilution of 2
8
 
HA units of each virus, strains Yucaipa, Bangor and BC, into the brains of twelve 1-day-old SPF 
chicks. Three birds from each group were sacrificed on 1, 2, 3 and 4 dpi and virus titers in brain 
tissue were assayed and expressed as TCID50 per gram of the brain in DF1 cells (Fig. 4.1).  
Neither of the two APMV-2 strains produced any clinical signs nor did they kill the chicks by 4 
dpi. Neither of the two APMV-2 strains was isolated from the brain homogenate of any of the 




were infected with NDV strain BC were either killed or sacrificed by 3 dpi and reached a titer of 
2.5x10
5
 TCID50/g of brain on day 3.  
 
Fig. 4.1 Growth kinetics of APMV-2 strains Yucaipa and Bangor in the brain of 1-day-old chicks 
and comparison with that of APMV-1 strain Beaudette C.  
Twelve 1-day-old chicks were inoculated with 0.05 ml of 1:10 dilution of 2
8 
HA units of APMV-
1 strain Beaudette C (BC), APMV-2 strains Yucaipa and Bangor via intracerebral route. Brain 
tissues were collected by sacrificing three birds from each group on 1, 2, 3 and 4 days post 
inoculation (dpi) or as and when any birds died of infection. Each time point represents the 
geometric mean of the individual virus titration from the brains of three birds.  
† All birds infected with APMV-1 strain BC were either dead or sacrificed by 3 dpi. 
 
4.5.3 Experimental infection of 4-week-old SPF chickens and turkeys. Groups of twelve 4-
week-old chickens were inoculated by the intranasal and intraocular routes with 2
8




either APMV-2 strain Yucaipa or Bangor. None of the chickens or turkeys displayed any overt 
clinical signs, and none of the birds died of disease. Further, there were no gross visceral 
pathological lesions in any of the birds at 2, 4, 6 and 14 dpi.  
 
4.5.4 Virus detection in tissues and swabs. Three birds from each of the four groups were 
euthanized on 2, 4 and 6 dpi. The following tissue samples were collected for virus detection by 
inoculation in embryonated chicken eggs: eyelid, trachea, lung, liver, spleen, brain, colon, caecal 
tonsil, bursa and kidney. Samples that were positive for virus, as measured by HA assay of egg 
allantoic fluid, were analyzed for virus quantitation using the TCID50 method in DF1 cells.  
Table 4.1 shows the distribution and titers of the viruses in various organs on different 
dpi of chickens. Strain Yucaipa was isolated from eyelids, respiratory tract (trachea and lungs) 
and alimentary tract (colon and caecal tonsils) in chickens. Although the virus was isolated from 
bursa in one of the chickens on 4 dpi, the titer of retrieved virus was very low. Strain Yucaipa 
was not detected in the brain or heart. Strain Bangor was isolated from the same tissues, although 
the number of virus-positive samples was somewhat less than for strain Yucaipa. In general, the 
titers in virus-positive tissue samples were similar for the two viruses. In addition, strain Bangor 
also was detected in the brain and heart in one bird each, but the titers were very low.  
In infected turkeys (Table 4.2), strain Yucaipa was isolated from the respiratory tract 
(trachea and lungs) and eyelids, but not from the alimentary tract. The virus titers in these organs 
were low compared to those from infected chickens. Strain Bangor was isolated from the 
respiratory tract (trachea and lungs) and the alimentary tract (caecal tonsils), and the virus titers 
were higher than those obtained from strain Yucaipa-infected turkeys. No virus of either strain 




strains, the number of virus-positive samples from all days was considerably less for turkeys than 
for chickens.  
The results of virus detection in oral and cloacal swabs are also presented in Tables 4.1 
and 4.2. In chickens, strain Yucaipa was detected in oral swabs on day 4 and in cloacal swabs on 
days 4 and 6. In comparison, strain Bangor was not detected in oral swabs from chickens but was 
detected in cloacal swabs like strain Yucaipa on days 4 and 6. In turkeys, strain Yucaipa was not 
detected in oral swabs but was detected in cloacal swabs on day 4. In comparison, strain Bangor 
was detected in oral swabs on day 6 and in cloacal swabs on days 4 and 6. In general, strain 
Yucaipa was detected less frequently in swabs from turkeys than from chickens, whereas the 
frequency of isolation of strain Bangor between the two species was similar. Virus detection in 
the swabs with either strain was most frequent in cloacal swabs, and was frequently detected on 
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1 - - - - - - - - - + 
2 - - - - - - - - - + 




1 - - - - - - - - - - 
2 - - - - - - - - - + 
3 - - - - 1.3X10
4
 - - - - + 
 
 
Table 4.1.  Viral distribution in tissues (measured by TCID50
*
)and virus isolation from oral and 
cloacal swabs (by inoculation in 9-day-old embryonated chicken eggs) in 4-week old chickens 
inoculated oculonasally with APMV-2 strains Yucaipa and Bangor on days 2, 4 and 6 post infection. 
 
*
TCID50 , 50% Tissue Culture Infective Dose  
 + = Virus was isolated  
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1 - - - - - - - - - - 
2 - 1.7X10
3
 - - - - - - - - 
3 - 1.9X10
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 - - - - - - - - - 
2 - - - - - - - - - - 
3 - 3.1X10
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 - - - - - - - - 
2 - 4.7X10
3
 - - - 1.2X10
4
 - - - + 
3 6.7X10
3
 - - - - 1.9X10
3




1 - - - - - - - - - - 
2 - - - - - - - - - - 




1 - - - - - - - - - - 
2 - - - - - - - - - + 
3 - - - - - - - - + + 
 
 
Table 4.2.  Viral distribution in tissues (measured by TCID50
*
) and virus isolation from 
oral and cloacal swabs (by inoculation in 9-day-old embryonated chicken eggs)in 4-week old 
turkeys inoculated oculonasally with APMV-2 strains Yucaipa and Bangor on days 2, 4 and 6 
post infection.  
 
*
TCID50 , 50% Tissue Culture Infective Dose 
+ = Virus was isolated  






4.5.5 Immunohistochemistry. The frozen sections of all the virus-positive tissue 
samples and some of the viral-negative control samples were immunostained using 
monospecific antibodies against N protein of APMV-2 strain Yucaipa. Large amounts 
of viral N antigens were detected consistently in all the tissue samples that were 
positive by virus isolation; no viral antigen was detected in tissue samples that were 
negative by virus isolation. However, no viral N antigens could be detected in the 
brain of a chicken infected with strain Bangor that was positive by virus isolation 
(Fig. 4.2).  
 
Fig. 4.2 Immunofluorescence of frozen tissues samples using monospecific antibody 
raised against APMV-2 nucleocapsid protein in rabbits.  2A: Lung from chicken no. 3 
infected with APMV-2 strain Yucaipa, 4 dpi; 2B: Caecal tonsil from chicken no. 3 
infected with APMV-2 strain Yucaipa, 4 dpi; 2C: Trachea from chicken no. 1 
infected with APMV-2 strain Yucaipa, 4 dpi; 2D: Colon from chicken no. 2 infected 
with APMV-2 strain Yucaipa, 4 dpi; 2E: Brain from chicken no. 2 infected with 
APMV-2 strain Bangor, 4 dpi.  
 





4.5.6 Seroconversion. An HI assay using chicken erythrocytes was performed with 
the sera collected from chickens and turkeys on 0, 2, 4, 6 and 14 dpi. The HI titers of 
the pre-infection chickens and turkeys were 2 or less. An HI titer of greater than 8 
was considered positive. All of the inoculated chickens and turkeys seroconverted 
from day 6 onwards. The mean HI titers in chickens for strains Yucaipa and Bangor 
was 1:40 and 1:40 on day 6 and 1:2560 and 1:2560 on day 14, and in turkeys was 
1:40 and 1:80 on day 6 and 1:2560 and 1:5120 on day 14, respectively.  
 
4.6 Discussion 
The APMVs are frequently isolated from a wide variety of avian species 
around the world. Currently, nine serological types of APMVs have been recognized, 
of these, the disease potential of APMV-1 (NDV) is well studied, but the disease 
potential of APMV-2 to APMV-9 is mostly unknown. Here, we have investigated the 
clinical disease and pathogenesis of APMV-2 strains Yucaipa and Bangor in chicken 
eggs, in 1-day-old chicks inoculated intracerebrally, and in 4-week-old chickens and 
turkeys inoculated via a natural route of infection. In this study, 4-week-old chickens 
and turkeys were chosen over the other age groups because at this age they are fully 
susceptible to viral infections. 
The APMV-2 strains Yucaipa and Bangor were first characterized by standard 
pathogenicity tests (MDT and ICPI). Results of MDT test showed that both the 
APMV-2 strains did not kill any of the chicken embryos even after seven days of 
inoculation. ICPI values of both APMV-2 strains were zero, indicating an absence of 




has been reported previously (McFerran et al, 1974; Shortridge and Burrows, 1997). 
Our MDT and ICPI values suggest that both strains are apathogenic to chickens. 
Since the APMV-2 strains did not kill 1-day-old chicks by intracerebral inoculation, 
we investigated whether the absence of neurovirulence was due to a lack of virus 
replication in the brain or whether replication occurred without any notable cell 
destruction. Our results showed that neither of the APMV-2 strains replicated 
detectably in the brains of the chicks. In contrast, all of the chicks that were 
inoculated with the mesogenic NDV strain BC died at 3 dpi, and the virus titers in the 
brain reached a value of 2.5X10
5
 TCID50/g. These results suggest that the absence of 
neurovirulence of APMV-2 strains was due to a lack of neurotropism rather than 
nonpathogenic replication. 
It has been previously shown that experimental infection of 1-day-old chicks 
with APMV-2 strain SCWDS ID AI02-1008, via the oculonasal route resulted in mild 
disease and that virus was isolated from trachea, lungs and gut for 7 dpi and from 
pancreas up to 28 dpi (Warke et al., 2008). In this study, we have evaluated the 
disease potential and pathogenesis of APMV-2 strains in 4-week-old SPF chickens 
and turkeys by the oculonasal route of infection. None of the infected birds showed 
any clinical signs of illness. In chickens, strain Yucaipa was isolated from tissues 
from both the respiratory and alimentary tracts while in turkeys the virus was isolated 
only from tissues from the respiratory tract and the titers of recovered virus were low. 
Each of the viruses was detected in oral and cloacal swabs from both chickens and 
turkeys, but strain Yucaipa was isolated less frequently from turkeys. Taken together, 




turkeys. On the other hand, strain Bangor was isolated from respiratory and 
alimentary tracts of both chickens and turkeys confirming that the virus replicated 
well in both the tracts in chickens and turkeys.  
Visceral gross lesions were not evident in any infected birds at 2, 4, 6 and 14 
dpi. Using IHC, viral N protein was detected in the same tissues that were positive by 
virus isolation except in a brain tissue that was positive by virus isolation but negative 
by IHC.  It is possible that the virus load in this infected brain tissue was too low to 
be detected by IHC or that the tissue was contaminated with virus during collection. 
In contrast, staining of the tissues that were negative by virus isolation was very weak 
or absent. An interesting finding was the presence of large amounts of viral antigens 
in epithelial cells, suggesting that these cells are highly permissive to viral replication 
and that extensive virus replication occurred. Thus, assays for infectious virus were 
considerably less sensitive than IHC in detecting virus replication in the inoculated 
birds. Another prominent finding of our IHC study was the presence of viral antigen 
only in the epithelial surfaces of these organs. There was no evidence of viral antigen 
in the sub epithelial portion of the tissues. This suggests that these viruses have a 
tropism for the superficial epithelial cells. Nonetheless, the detection of viral antigen, 
and in some cases infectious virus, in multiple internal organs of the birds indicates 
that both viruses were capable of replication in multiple tissues rather than being 
restricted to the respiratory and alimentary tracts. Presumably, the virus reached the 
various internal organs through the blood stream. Nonetheless, this extensive amount 




These results show that APMV-2 strains are capable of infecting adult 
chickens and turkeys using a possible natural route of infection. Serological titers 
demonstrated a humoral response in all of the birds inoculated with either APMV-2 
strain, a further indication of successful replication. However, our results suggest that 
chickens are comparatively more susceptible than turkeys to APMV-2 infection. 
The fusion F protein cleavage site of NDV is a well characterized determinant 
of NDV pathogenicity in chickens (Millar et al., 1988; de Leeuw et al., 2003; Panda 
et al., 2004). Virulent NDV strains typically contain a polybasic cleavage site that 
contains the preferred recognition site for furin (R-X-K/R-R↓), which is an 
intracellular protease that is present in most cells. This provides for efficient cleavage 
in a wide range of tissues, making it possible for virulent strains to spread 
systemically. In contrast, avirulent NDV strains typically have basic residues at the 
−1 and −4 positions relative to the cleavage site and depend on secretory protease (or, 
in cell culture, added trypsin) for cleavage. Also, whereas the first amino acid of the 
newly-created F1 terminus is phenylalanine for virulent NDV strains, it is leucine for 
avirulent NDV strains, an assignment that also reduces the efficiency of cleavage 
(Morrison et al., 1993). The inability to be cleaved by furin limits the replication of 
avirulent strains to the respiratory and enteric tracts where secretory protease is 
available for cleavage. The putative F protein cleavage site of APMV-2 strain 
Yucaipa (DKPASR↓F) and strain Bangor (TLPSAR↓F) have one or two basic 
residues (underlined), which is similar but not identical to the pattern of avirulent 
NDV strains. Conversely, the F1 subunit of both the APMV-2 strains begins with a 




leucine residue, as seen in most avirulent NDV strains (Collins et al., 1993). APMV-2 
strains Yucaipa and Bangor replicated in a wide range of cells in vitro without the 
addition of exogenous protease and the inclusion of protease did not improve the 
efficiency of replication. In the present study, the APMV-2 strains were detected 
abundantly in various internal organs, suggesting a systemic spread of the virus. 
These results confirm our in vitro findings that APMV-2 is capable of efficient 
intracellular cleavage in the absence of an apparent furin motif in F protein, and show 
that this confers the ability to spread systemically.  
In conclusion, we have shown that adult SPF chickens and turkeys are 
susceptible to APMV-2 infection without causing overt signs of clinical disease. 
However, in commercial chickens and turkeys the disease picture could be quite 
different depending on management practices, environmental conditions and other 
concomitant infections. This study has demonstrated that APMV-2 has an affinity for 
epithelial linings of respiratory and intestinal tracts and lacks the ability to grow in 
neural tissues, but does spread systemically. Further studies are needed to understand 




Chapter 5:  
 
5.1 Title  
Establishment of a reverse genetics system for Avian Paramyxovirus serotype 
2 (APMV-2) and rescue of recombinant APMV-2 expressing foreign protein, EGFP. 
 
5.2 Abstract 
The full-length cDNA clone of APMV-2/Yuc was constructed as six different 
subgenomic fragments in a transcription plasmid pBR322/dr/Yuc between the T7 
RNA polymerase promoter and autocatalytic hepatitis delta virus ribozyme. The 
plasmid pBR322/dr/Yuc was generated by cloning a 73-nucleotide (nt) 
oligonucleotide linker sequence containing unique restriction enzymes between Asc I 
and Rsr II enzyme sites of pBR322/dr plasmid.  The support plasmids expressing N 
and P were constructed in pGEM7z(+) and L was cloned into pTM1 vector, all under 
T7 promoter. Transfection of the full length cDNA plasmid into HEp-2 cells and 
infection with recombinant modified vaccinia strain Ankara expressing the T7 RNA 
polymerase (MVA-T7) resulted in the synthesis of antigenomic RNA of APMV-
2/Yuc. The cotransfection of the support plasmids resulted in replication and 
transcription of the antigenomic RNA leading to generation of recombinant virus. The 
recombinant virus thus recovered was amplified in 9-day-old embryonated SPF 
chicken eggs and was confirmed for the presence of the artificially introduced 
restriction enzyme site markers using RT-PCR and sequencing. The in vitro growth 




2/Yuc. Furthermore, two recombinant viruses, rAPMV-2/Yuc/EGFP and rAPMV-
2/Yuc/kozakEGFP, expressing enhanced green fluorescent protein (EGFP) as foreign 
protein were also recovered and characterized. The growth pattern of GFP-expressing 
recombinant viruses was similar to the recombinant parental virus. Both the 
recombinant viruses stably expressed EGFP for at least five serial passages in 9-day-
old embryonated chicken eggs and in DF1 cells. This result shows that the established 
reverse genetics system can be used to engineer APMV-2/Yuc to express a foreign 




Avian Paramyxovirus serotype 2 strain Yucaipa (APMV-2/Yuc) was first 
isolated in 1956 at Yucaipa, California, from a diseased chicken (Bankowski et al., 
1960). It is associated with mild respiratory illness in chickens and turkeys, which 
gets exaggerated with secondary bacterial infections. APMV-2 is classified along 
with eight other APMV serotypes in the genus Avulavirus within the subfamily 
Paramyxovirinae in the family Paramyxoviridae. APMV-2 has a 14,904-nt long, non-
segmented, negative-sense RNA genome, which encodes six genes N, P, M, F, HN 
and L and at least eight proteins N, P/V/W, M, F, HN and L (Subbiah et al., 2008).  
The knowledge of the complete viral genome sequence is essential for genetic 
manipulation through a reverse genetics system, rendering recovery of recombinant 
virus entirely from cloned cDNA (reviewed in Collins and Murphy, 2002, Neumann 




plasmid based approach, where in, four plasmids – one encoding the viral anti-
genome and the others encoding the viral polymerase complex (N, P and L proteins), 
all under the control of T7 promoter are cotransfected in permissive cells expressing 
T7 RNA polymerase or in cells infected with recombinant vaccinia virus expressing 
T7 RNA polymerase. The reverse genetics system can be applied for the genetic 
manipulation of viruses to study their molecular biology and pathogenesis and 
secondly, for development of vaccine vectors against important and emerging 
pathogens by engineering viruses to express foreign immunogens (Khattar et al., 
2010; Bukreyev et al., 2010; Billeter et al., 2009; Buchholz et al., 2006).  
This study describes the recovery of recombinant APMV-2/Yuc entirely from 
cloned cDNA using a reverse genetics system. The rescued recombinant virus was 
biologically similar to the wild-type APMV-2/Yuc. Furthermore, we have recovered 
recombinant viruses expressing enhanced green fluorescent protein (EGFP), with and 
without kozak sequence, to evaluate potential of APMV-2 as a vaccine vector. The 
EGFP-expressing recombinant viruses were biologically similar to the parental 
recombinant and wild-type virus, and stably expressed GFP for at least five 
consecutive passages suggesting that this system could be used to develop vaccine 
vectors.  
 
5.4 Materials and Methods 
 
5.4.1 Cells and Virus. DF-1 cells (Chicken embryo fibroblast cell line) and HEp-2 




Dulbecco‟s modified Eagle‟s medium (DMEM), supplemented with 10% fetal bovine 
serum (FBS). APMV-2 strain Yucaipa (APMV-2/Yuc) was obtained from the 
National Veterinary Services Laboratory, Ames, Iowa. The wild-type as well as the 
recombinant viruses were propagated in the allantoic cavity of 9-day-old 
embryonated specific pathogen free (SPF) chicken eggs. After 72 h of infection, the 
allantoic fluids were harvested and titrated by hemagglutination assay (HA) using 
0.5% chicken RBC at room temperature. The recombinant modified vaccinia virus 
strain Ankara expressing the T7 RNA polymerase (a generous gift of Bernard Moss, 
National Institute of Health) was grown in primary chicken embryo fibroblast cells.  
 
5.4.2 Construction of support plasmids. For constructing the support plasmids, the 
cDNAs bearing the open reading frame (ORF) of nucleocapsid protein (N) and 
phosphoprotein (P) were cloned into expression vector pGEM7z(+) (Promega, WI, 
USA) under T7 promoter between Sph I and Hind III, Eco R I and Sac I, respectively.  
The ORF of large polymerase protein (L) was subcloned as two fragments into pTM1 
vector (possessing the encephalomyocarditis virus internal ribosome entry site (IRES) 
downstream of the T7 RNA polymerase promoter and using the translation initiation 
codon contained in the Nco I site of the IRES) between the enzyme sites Nco I, Stu I 
and Sac I. The Sac I enzyme site was artificially created by G11468C mutation within 
L ORF without changing any amino acids. Briefly, RNA was isolated from the 
allantoic fluid of APMV-2/Yuc-infected eggs, 72 h post infection using RNeasy kit 
(QIAGEN, USA) according to the manufacturer‟s instructions. The cDNA fragments 




performed with Superscript II reverse transcriptase (Invitrogen) and gene specific 
primers. The primers used in the RT-PCR are listed in Table 1. The N, P and L 
support plasmids (pN, pP and pL) were used for the recovery of the recombinant 
viruses.   
 
N ORF      +  5‟ ACATGCATGCATGTCTTCTGTGTTTTCAGAATACCAGG 3‟ 
                   -  5‟ CCCAAGCTTTCACCAATCTAATGAGGCCGCATCATTG 3‟ 
 
P ORF      +  5‟ CCGGAATTCATGGAGTTCACCGATGATGCCGAAA-                                 
                            -TTGCTGAGCTG 3‟ 
                  -  5‟ TGACGAGCTCCTAGGCATTGTATATCTG 3‟ 
 
L ORF   Fragment 1: +  5‟ CATGCCATGGATCAAACTCAAGCTGACA 3‟  
                                      -   5‟ CCCCTTGAGGAGCTCTATAGTGTCTGGAGA 3‟ 
 
               Fragment 2: + 5‟ TCTCCAGACACTATAGAGCTCCTCAAGGGG 3‟ 
                                      -  5‟ AAAAGGCCTTTAATTGCTTGCATTTCTGAAC- 
                                               -TTCATACAGC 3‟ 
 
Table 5.1. The list of oligonucleotide primers used in the synthesis of cDNA 
fragments of N, P and L ORFs. The restriction enzyme sites artificially created in the 
primers are underlined.  
 
5.4.3 Construction of full length plasmid. The restriction enzyme profile of the 
complete genome sequence of APMV-2/Yuc was analyzed by SeqBuilder software 
(DNASTAR Lasergene 8) to facilitate cloning the full length cDNA into a low copy 
plasmid pBR322/dr. Plasmid pBR322/dr was a modified form of plasmid pBR322 
which contained a 72-nt oligo linker between the EcoR I and Pst I sites and hepatitis 
delta viral 84-nt antigenome ribozyme sequence and T7 RNA polymerase 




al., 2000). A 73-nt oligo linker with unique restriction enzyme sites was synthesized 
and inserted between Asc I and Rsr II sites of the pBR322/dr vector to generate 
pBR322/dr/Yuc for cloning the full length APMV-2/Yuc. The antigenomic cDNA of 
APMV-2/Yuc (14,904 nt) was divided into six fragments and sequentially cloned into 
pBR322/dr/Yuc plasmid between the T7 promoter and Hepatitis delta ribozyme 
sequence. A total of five unique restriction enzyme sites were created in the full 
length by mutating 10 nt without changing any amino acids (Fig. 5.1). For cloning, 
RNA was isolated from the allantoic fluid of APMV-2/Yuc-infected eggs at 72 h post 
infection, using RNeasy kit. All RT reactions were carried out using Superscript II 
reverse transcriptase (Invitrogen). The primers used for RT-PCR of the six fragments 
are listed in Table 3.2. The unique restriction enzyme sites in the full length were 
generated by the following 10 mutations: C2923A, G2924A, T2925A, G2926C, 
G4154C, G5971A, A5973T and T7870C in the untranslated regions (UTRs), 
A11321G and A11322C within L ORF without changing any amino acids. After 
ligation into the plasmid, each cDNA fragment was sequenced completly. The 
APMV-2/Yuc full length plasmid was called pAPMV-2/Yuc and had three non-viral 
G residues adjacent to the T7 promoter, at the 5' end of the antigenome, to enhance 







Fig. 5.1 Generation of full length cDNA clone of APMV-2/Yuc.  
The full length cDNA clone was constructed by assembling  six subgenomic 
fragments  into pBR322/dr/Yuc using a 73-nt long oligonucleotide linker sequence 
between T7 RNA polymerase promoter sequence and the hepatitis delta ribozyme 
sequence, which was followed by T7 terminator sequence (between the restriction 
enzyme sites AscI and RsrII).  The ten nt mutations and their positions, that were 
made to create the unique restriction enzyme sites in the full length, are represented 





Table 5.2. Oligonucleotide primers used for construction of the full-length cDNA  
 
5.4.4 Construction of full length plasmids expressing EGFP, with and without 
kozak sequence. The plasmid pAPMV-2/Yuc was modified by the insertion of a 
transcription cassette containing the ORF for enhanced green fluorescent protein 
(EGFP) (Clontech, Inc.). The ORF of EGFP was flanked by the Pme I enzyme site, a 
10-nt putative P gene-end (TAACAAAAAA), 1-nt intergenic sequence (T), 1-nt 
5‟UTR (T), a 10-nt putative M gene-start (GGGGGCGAAG) upstream and by the 













+ 5' TCATTGGCGCGCCTAATACGACTCACTATAGGGACC- 
         -AAACAAGG 3’ 







+ 5' TCACCAGTTTAAACCCACATGCTTCCCTGC 3' 







+ 5' GACACGTGCGGCCGCACACCTC 3' 







+ 5' GAGAGGTTAATTAAGCCTAAACATGAT 3' 






+ 5' CAAAAGCCACGTAGTGTCTAACAGC 3' 






+ 5’ CATTCGAGCCGCGGAAGGAAATA 3’ 
- 5’ ATGCCCAGGTCCGGACCGCGAGGAGGTGGAGATG- 







cloned between P and M genes in the full length plasmid to generate the pAPMV-
2/Yuc/EGFP plasmid (Fig. 5.2). Additionally, plasmid pAPMV-2/Yuc/kozakEGFP was 
constructed by inserting a 6-nt kozak sequence (GCCACC) in front of the start codon 
of EGFP ORF (Fig. 5.2). The length of the encoded rAPMV-2/Yuc/EGFP and 
rAPMV-2/Yuc/kozakEGFP antigenomes, excluding the non-viral sequences, were 







Fig. 5.2 Construction of full length plasmids expressing EGFP, with and without 
kozak sequence.  
The top panel (A) shows the construction of full length plasmid, pAPMV-
2/Yuc/EGFP and the bottom panel (B) shows the construction of pAPMV-




inserted as a transcription cassette at the Pme I site (at the putative P gene 5‟ UTR). 
This cassette contained the EGFP ORF flanked by a T residue as the 5‟UTR, M gene-
start (M GS), followed by a T residue as the intergenic sequence (IGS), P gene-end (P 
GE) and Pme I enzyme site. The EGFP ORF was flanked at the downstream end by 
another Pme I enzyme site. In the pAPMV-2/Yuc/kozakEGFP, the kozak sequence 
(GCCACC) was inserted before EGFP ORF.   
 
5.4.5 Transfection and recovery. The recombinant viruses were recovered from the 
full length plasmids as described previously (Krishnamurthy et al., 2000). Briefly, in 
a six well plate, HEp-2 cells (80-90% confluent) were infected with MVA-T7 at a one 
focus forming unit per cell and then transfected with pNP (3 μg), pP (2 μg), pL (1 μg) 
and pAPMV-2/Yuc (3-5 μg) or the full length plasmids containing EGFP gene. 
Lipofectamine (Invitrogen, USA) was used for transfection according to the 
manufacturer‟s protocol. After 6 h of transfection, the supernatant was discarded and 
fresh DMEM containing 0% FBS was added. The supernatant was collected after 48 
h and passaged in 9-day-old embryonated SPF chicken eggs to remove residual 
vaccinia virus. The allantoic fluid was harvested at 3 dpi and tested for HA activity 
(Fig. 3). The recovered viruses were passaged five times in 9-day-old embryonated 
SPF chicken eggs and RT-PCR and sequencing confirmed the recombinant viruses. 






Fig. 5.3 A Plasmid based system for recovery of recombinant APMV-2/Yuc from 
cDNA. 
 HEp-2 cells were first infected with recombinant vaccinia virus expressing T7 
polymerase and cotransfected with antigenome full length cDNA plasmid pAPMV-
2/Yuc and expression plasmids pN, pP, pL. This cartoon depicts the events that occur 
in the transfected HEp-2 cell leading to the recovery of recombinant viruses. 
 
5.4.6 Identification of genetic markers in recombinant viruses by RT-PCR and 
sequencing. RT-PCR was performed on the RNA extracted from recombinant viruses 
using P gene-specific forward primer, P-2629 (5‟-
CTCCTGAGGTCACAGAAGGAGG-3‟) and M gene-specific reverse primer, M-




digested using Pme I enzyme and sequenced to confirm the Pme I site. The same 
primers were used to amplify the GFP gene in the recombinant viruses and DNA 
sequencing confirmed the presence of the restriction enzyme site, the GFP ORF and 
the kozak sequence. RNA isolated from wt APMV-2/Yuc was included as a control. 
Furthermore, the GFP expression by the recombinant viruses was determined by 
monitoring the virus-infected DF1 cells under fluorescence microscope. 
 
5.4.7 Immuno staining of infected cells. The recombinant viruses were grown in 
DF1 cells and overlaid with 0.8% methyl cellulose (Sigma) in DMEM without FBS. 
The infected cells were incubated in 37⁰C incubator. After three days of infection, the 
overlay was removed and the cells were fixed with methanol at room temperature for 
30 min. The cells were then washed and incubated with polyclonal antisera raised 
against wt APMV-2/Yuc in chickens at 1:500 dilutions for 1 h followed by incubation 
for 45 min with goat anti-chicken IgG conjugated with horseradish peroxidase (KPL, 
MD, USA). The virus infected cells were detected under light microscope after 
staining with DAB substrate (Vector Labs, USA).    
 
5.4.8 Growth kinetics of recombinant viruses and wild-type virus. Briefly, the 
DF1 cells were grown in six-well plates as monolayer (80% confluency) and infected 
in triplicates with the following viruses (MOI of 1); wt APMV-2/Yuc, rAPMV-
2/Yuc, rAPMV-2/Yuc/EGFP and rAPMV-2/Yuc/kozakEGFP. The supernatants were 
collected at 24, 48, 72, 96, and 120 h post-infection (p.i). Virus titers in the 




with DF1 cells. The infected cells were stained by immunoperoxidase staining using 
polyclonal antibody raised against wt APMV-2/Yuc in chickens. Virus titers 
(TCID50/ml) were calculated using Reed & Muench method (Reed & Muench, 1938).  
 
5.4.9 Pathogenicity tests. The virulence of the recombinant viruses was compared 
with the wt APMV-2/Yuc by the internationally accepted standard pathogenicity 
tests: mean death time (MDT) in 9-day-old embryonated SPF chicken eggs and 
intracerebral pathogenicity index (ICPI) in 1-day-old SPF chicks (Alexander 1989).  




) dilutions of fresh infective 
allantoic fluid in PBS was made and 0.1 ml of each diluent was inoculated into the 
allantoic cavities of five 9-day-old SPF embryonated chicken eggs (BEE eggs 
company, PA) and the eggs were incubated at 37
o
C. The eggs were candled 3 times a 
day for the next 7 days, and the time of embryo death if any were recorded. The 
minimum lethal dose (MLD) is the highest virus dilution that kills all the embryos. 
The MDT is the mean time in hours for the MLD to kill all the inoculated embryos.  
For ICPI, 0.05 ml (1:10 dilution) of fresh infective allantoic fluid of each virus 
was inoculated into groups of ten 1-day-old SPF chicks via the intracerebral route. 
The inoculation was done using a 27-gauge needle attached to a 1 ml stepper syringe 
dispenser that was set to dispense 0.05 ml of inoculum per bird. The birds were 
inoculated by inserting the needle up to the hub into the right or left rear quadrant of 
the cranium. The birds were observed for clinical symptoms and mortality, once 
every 8 h for a period of 10 days. At each observation, the birds were scored: 0 if 




the 10-day period. Highly virulent (velogenic) viruses give values approaching 2 and 




5.5.1 Construction of support plasmids expressing N, P and L proteins. The 
support plasmids, pN and pP were generated by inserting the cDNA bearing the ORF 
of N, P into expression vector pGEM7z(+) between Sph I and Hind III, Eco R I and 
Sac I, respectively, while pL was obtained by cloning the L ORF as two fragments 
into pTM1 vector using the enzyme sites Nco I, Stu I and Sac I. The Sac I enzyme 
site was artificially created by G11468C mutation within L ORF without changing 
any amino acids. The support plasmids were confirmed by digesting with 
corresponding restriction enzymes and DNA sequencing of the complete ORF, prior 
to using them in the recovery of the recombinant viruses (Fig. 5.4).  
    
Fig. 5.4 Confirmation of the presence of ORFs inserted in the support plasmids, pN, 




The plasmids, pN (B), pP (D) and pL (F) were digested using the restriction enzymes, 
Sph I and Hind III for N ORF(A), Eco R I and Sac I for P ORF(C) and Nco I, Sac I 
and Stu I for L ORF (E).  Lane M is 1kb plus DNA marker.  
 
5.5.2 Construction of the full length cDNA clone of APMV-2/Yuc. In order to 
construct the full length cDNA of APMV-2/Yuc, pBR322/dr/Yuc, the whole APMV-
2 genome was divided into six fragments and they were sequentially cloned. Each 
fragment represented one gene except the first fragment that included both N and P 
genes and fragments 5 and 6 together constituted the large L gene. A 73-nt oligo 
linker was synthesized to contain unique restriction enzyme sites and was inserted 
between Asc I and Rsr II sites of the pBR322/dr vector to clone the full length cDNA. 
The DNA sequence results of the entire full length cDNA confirmed ten nucleotide 
mutations, C2923A, G2924A, T2925A, G2926C, G4154C, G5971A, A5973T, 
T7870C, A11321G and A11322C which were artificially created to generate unique 
restriction enzyme sites and served as the genetic markers in recombinant viruses. 
 
5.5.3 Construction of full length plasmids encoding EGFP with and without 
kozak sequence. The full length plasmid encoding the EGFP, pAPMV-2/Yuc/EGFP, 
was constructed by inserting the EGFP transcription cassette at Pme I site between P 
and M genes. The EGFP ORF was inserted between the genes P and M since this 
position is known to support stable expression of foreign genes without affecting 
virus replication. The EGFP cassette contained appropriate viral GS and GE signals 




sequence in front of the EGFP ORF. The kozak sequence was introduced to 
determine whether the sequence can enhance the levels of GFP expression. The 
plasmids were sequenced to confirm the insertion of foreign cassette at the Pme I site.  
 
5.5.4 Recovery of infectious recombinant viruses. The transfection of full length 
cDNA plasmids pAPMV-2/Yuc, pAPMV-2/Yuc/EGFP and pAPMV-
2/Yuc/kozakEGFP along with support plasmids pN, pP and pL in HEp-2 cells infected 
with MVA-T7, yielded infectious recombinant viruses two days after transfection. 
The recovered viruses were passaged in 9-day-old embryonated SPF chicken eggs to 
amplify the recombinant viruses (rAPMV-2/Yuc, rAPMV-2/Yuc/EGFP and rAPMV-
2/Yuc/kozakEGFP). RT-PCR of the infective allantoic fluid and DNA sequencing 
confirmed the presence of genetic markers and the GFP.  
 
Fig. 5.5 Identification of genetic marker in the recombinant virus. RT-PCR of the 
region containing the Pme I site was done using primers flanking the Pme I restriction 
enzyme site, between P and M genes, and the DNA was sequenced to confirm the 
presence of the mutations, C2923A, G2924A, T2925A and G2926C, that served as 





5.5.5 In vitro characterization of recombinant viruses. The morphological 
characteristics of recombinant viruses were similar to wild-type virus in DF1 and 
Vero cells (refer to Chapter 3). None of the recombinants produced plaques but 
caused single cell infections comparable to wild-type APMV-2 and the maximum 




Fig. 5.6 The Cytopathic effects of wild type APMV-2/Yuc and rAPMV-2/Yuc in DF1 
cells. The DF1 cells were infected with wild type APMV-2/Yuc and rAPMV-2/Yuc 
at an MOI of 1 or mock infected with PBS and observed for the cytopathic effects on 
3 day post infection (dpi). The lower panel shows immunoperoxidase staining of 
infected cells on 3 dpi using polyclonal sera against APMV-2/Yuc raised in chickens. 





The GFP expression by the recovered viruses was confirmed by infecting DF1 
cells with rAPMV-2/Yuc/EGFP and rAPMV-2/Yuc/kozakEGFP (Fig. 5.7). Both the 
viruses expressed GFP and caused single cell infections as seen in wild type APMV-
2/Yuc.  
 
Fig. 5.7 Expression of enhanced GFP by rAPMV-2/Yuc/EGFP and rAPMV-
2/Yuc/kozakEGFP.  DF1 cells were infected with rAPMV-2/Yuc, rAPMV-
2/Yuc/EGFP and rAPMV-2/Yuc/kozakEGFP viruses at an MOI of 1. The infected DF1 
cells were observed each day for the expression of GFP under fluorescence 
microscope. The rAPMV-2/Yuc/EGFP and rAPMV-2/Yuc/kozakEGFP viruses, both 
stably expressed GFP for atleast five serial passages in DF1 cells. The scattered green 
fluorescent cells were typical of the single cell infection phenotype seen with wt 
APMV-2/Yuc infection.  
 
The recovered viruses, rAPMV-2/Yuc, rAPMV-2/EGFP, rAPMV-2/kozakEGFP 
were compared with the parental wild-type virus for their in vitro growth 
characteristics by multiple-step growth kinetics in DF1 cells at an MOI of 1 (Fig. 
5.8). The kinetics and the magnitude of replication of the recombinant viruses were 




expressing GFP was 1.5 log lower than those of the wild-type virus, suggesting that 
the insertion of foreign gene resulted in virus attenuation. The virus titer of wt 











 TCID50/ml, respectively, on 4 dpi  
 
Fig. 5.8 Comparison of growth kinetics of wild type APMV-2/Yuc and rAPMV-
2/Yuc, rAPMV-2/Yuc/EGFP and rAPMV-2/Yuc/kozakEGFP.  
Briefly, DF1 cells in six-well plates were infected in triplicates with wild type 
APMV-2/Yuc and the recombinant viruses, rAPMV-2/Yuc, rAPMV-2/Yuc/EGFP 
and rAPMV-2/Yuc/kozakEGFP, at an MOI of 1 and samples were collected from the 
culture supernatant at 24 h interval until 120 h post-infection. Virus titers of the 
samples were determined by serial end-point dilution in 96-well plates seeded with 




type APMV-2/Yuc, raised in chickens. Virus titres (TCID50/ml) were calculated using 
Reed & Muench method (Reed & Muench, 1938).  
 
5.5.6 Pathogenicity tests. The virulence of the recombinant viruses were compared 
with wt APMV-2/Yuc by two internationally accepted tests namely; MDT in 9-day-
old embryonated SPF chicken eggs and ICPI in 1-day-old SPF chicks. The 
recombinant viruses did not kill the chicken embryos even after 7 dpi and had ICPI 
value of zero, suggesting that the recovered recombinant viruses were avirulent, 
similar to the wild type APMV-2/Yuc. 
 
5.6 Discussion 
This study describes the recovery of infectious recombinant APMV-2 strain 
Yucaipa from the cloned cDNA by reverse genetics system for the first time. The 
availability of the complete genome sequence of APMV-2/Yuc assisted in generating 
the full length cDNA clone, required for recovery of infectious recombinant virus. In 
this system, recombinant vaccinia virus expressing T7 RNA polymerase (MVA-T7) 
was used to synthesize the antigenomic RNA from the full-length plasmid and the 
proteins N, P, and L from the cotransfected support plasmids, pN, pP and pL. Similar 
system has been used to recover other viruses (rabies virus, Schnell et al., 1994; 
vesicular stomatitis virus, Lawson et al., 1995; human respiratory syncytial virus, 
Collins et al., 1995; measles virus, Radecke et al., 1995; Sendai virus, Garcin et al., 
1995; SV5, He et al., 1997; rinderpest virus, Baron and Barrett, 1997; parainfluenza 




2001; Newcastle disease virus, Peeters et al., 1999 and Krishnamurthy et al., 2000; 
AMPV-A, Naylor et al., 2004, AMPV-C, Govindarajan et al., 2006). The growth 
characteristics of the recombinant virus, rAPMV-2/Yuc generated in this study was 
similar to that of the wild-type virus. The rAPMV-2/Yuc produced single cell 
infections in DF1 and Vero cells and was antigenically similar to wild type APMV-
2/Yuc, as observed by immunoperoxidase staining of the infected cells. These results 
indicate the possibility of recovering a wild-type-virus-like recombinant virus entirely 
from cloned cDNA.  
One of the important applications of reverse genetics system is the 
development of vaccine vectors by engineering viruses to express foreign 
immunogens. Paramyxovirus vectors have several advantages as follows; the ability 
to accommodate large foreign genes without drastic reduction in virus growth (Sakai 
et al., 1999; Haglund et al., 2000 and Huang et al., 2001 and Biacchesi et al., 2004), 
stable expression of the inserted foreign genes even after many passages in vitro 
(Bukreyev et al., 1996, Mebatsion et al., 1996; He et al., 1997 and Biacchesi et al., 
2004a) and finally, the absence of homologous RNA recombination makes them safe 
and stable vectors (Lamb and Kolakofsky, 1996 and Palese et al., 1996).  
Using the established reverse genetics system, rAPMV-2 expressing foreign 
protein, enhanced GFP, was recovered. Two full length cDNA constructs were made, 
one with EGFP transcript cassette alone between P and M gene while the other also 
had kozak sequence in front of EGFP ORF. The enhanced GFP was preferred as the 
foreign gene mainly because of the small size and the ease of visualization of the 




clone was chosen for insertion of EGFP because paramyxoviruses show gradient 
transcription pattern wherein the genes located near the 3‟ end of the genome are 
transcribed and expressed in higher quantities than those further behind, also 
previously it has been shown that the expression of foreign genes are better when 
placed near the 3‟ end (Sakai et al., 1999; Wertz et al., 1998). The reason behind 
using kozak sequence in one of the construct was to see if it improved the GFP 
expression, as kozak sequence is known to optimize protein translation after mRNA 
synthesis (Kozak, 1987; Kozak, 1990). The recovered viruses were similar to the 
parental virus in their growth characteristics but they were attenuated, the viral titers 
were 1.5 log lower than the parental virus. The attenuation following the expression 
of foreign genes has also been reported in other paramyxoviruses (Krishnamurthy et 
al., 2000 and Biacchesi et al., 2004a). There was not much difference in the GFP 
expression between rAPMV-2/Yuc/EGFP and rAPMV-2/Yuc/kozakEGFP suggesting 
that the inserted kozak sequence did not affect the expression level of GFP. Both the 
recombinant viruses stably expressed the foreign protein for at least five serial 
passages in 9-day-old embryonated SPF chicken eggs and in DF1 cells.  
In conclusion, a reverse genetics system was established for APMV-2 and the 
recovered recombinant virus showed similar morphological and in vitro growth 
characteristics and pathogenicity to the wild type virus.  The reverse genetics system 
can be used as a tool to understand the APMV-2 molecular biology and pathogenesis. 
Furthermore, the ability to engineer recombinant APMV-2/Yuc expressing a foreign 
gene has been demonstrated using enhanced GFP, which has implications in the 







Effect of fusion protein cleavage site mutations on virulence and 
pathogenicity of avian paramyxovirus serotype 2 
 
6.2 Abstract 
Avian Paramyxovirus (APMV) serotype 2 is one among the nine serotypes of 
APMV that infect a wide variety of avian species around the world. APMV-2 strains 
cause mild respiratory illness in chickens and turkeys. To elucidate the molecular 
basis of the low pathogenicity of these strains we have constructed a reverse genetics 
system for recovery of infectious recombinant APMV-2 strain Yuc (APMV-2/Yuc) 
from cloned cDNAs. The rescued virus (rAPMV-2) resembled the parental wild type 
virus in growth properties in vitro and in pathogenicity in vivo. We have used the 
reverse genetics to analyze the role of the putative cleavage site of fusion (F) protein 
on pathogenesis and virulence of APMV-2. The F protein of APMV-2 is a type I viral 
glycoprotein and shares features common to other paramyxovirus F proteins. The F 
protein cleavage site of APMV-2 has two basic amino acid residues and a 
phenylalanine at the beginning of F1 subunit. APMV-2 does not require exogenous 
protease supplementation for growth in cell culture and causes single-cell infections 
without forming syncytia. A total of twelve APMV-2 mutants with F protein cleavage 
site sequences resembling APMV-2 serotypes 1 to 9 were generated. Our results 




propagations in embryonated chicken eggs. Any change in the amino acid sequence at 
the F protein cleavage site resulted in syncytia formation and a slight increase in the 
virus replication in cell culture, suggesting proteolytic processing of the F protein. 
However, pathogenicity tests in 9-day-old embryonated chicken eggs and in 1-day-
old chicks showed that the mutants were completely non-virulent like the parental and 
wild type virus. Experimental infection of 2-week-old chickens showed that the 
mutants were not different from the parental virus in terms of tissue tropism and 
pathogenesis. These results demonstrated that genetically modified APMV-2 can be 
recovered from cloned cDNA and suggested that cleavage of the F protein is not a 
determinant of pathogenicity of APMV-2.  
 
6.3 Introduction 
Paramyxoviruses are pleomorphic, enveloped viruses containing a non-
segmented, negative-sense, RNA genome. These viruses have been isolated from a 
great variety of mammalian and avian species around the world (Lamb et al., 2005). 
All paramyxoviruses that have been isolated to date from avian species segregate into 
genus Avulavirus, representing avian paramyxoviruses (APMV) and genus 
Metapneumovirus, representing the avian metapneumoviruses in the family 
Paramyxoviridae. APMVs have been divided into nine different serotypes (APMV 1 
through 9) based on hemagglutination-inhibition (HI) and neuraminidase-inhibition 
(NI) tests (Alexander, 2003). APMV-1 comprises of all strains of Newcastle disease 
virus (NDV) and is the most completely characterized serotype due to the severity of 




and reverse genetics system are available for representative NDV strains: lentogenic 
strain LaSota (Huang et al., 2001; Romer Oberdorfer et al., 1999 ; Peeters et al., 
1999), B1 (Nakaya et al., 2001), mesogenic strain Beaudette C (Krishnamurthy et al., 
2000) and velogenic strain Hert/33 (de Leeuw et al., 2005). As a first step in 
characterizing the other APMV serotypes, complete genome sequences of APMV 
serotypes 2 to 9 were recently determined, expanding our knowledge about these 
viruses (Chang et al., 2001; Subbiah et al., 2008; Kumar et al., 2008; Nayak et al., 
2008; Jeon et al., 2008; Samuel et al., 2009; Paldurai et al., 2009; Xiao et al.,   2009; 
Samuel et al., 2010).  
APMV-2 was first isolated from a diseased chicken in 1956 in Yucaipa, 
California (Bankowski et al., 1960). Since then many APMV-2 strains have been 
isolated from domestic poultry, free range, captive and wild birds around the world 
(Alexander & Senne, 2008). APMV-2 infections have been reported in chickens in 
United States, Canada, Russia, Japan, Israel, India, Saudi Arabia, Costa Rica and 
from turkeys in United States, Canada, Israel, France and Italy (Alexander 2000). The 
infection is more prevalent in turkeys than chickens (Bankowski et al., 1968). 
APMV-2 infection was shown to affect hatchability and poult yield in turkeys 
(Bankowski et al., 1981). APMV-2 was found to cause drop in egg production in 
commercial layer and broiler breeder farms in Scotland (Wood et al., 2008). APMV-2 
viruses also have been frequently isolated from passerine and psittacine birds. 
Surveillance of wild birds has indicated that APMV-2 viruses are more frequent in 




The genome of APMV-2 strain Yucaipa is 14,904 nucleotides (nt) in length 
and contains a leader sequence at 3‟ end of 55 nt length and a trailer sequence at 5‟ 
end of 154 nt length. The genome consists of six genes that encode nucleocapsid 
protein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), 
hemagglutinin-neuraminidase protein (HN) and large protein (L). The genes are 
flanked on either side by highly conserved transcription start and stop sequences and 
have intergenic sequences of varying length. In common with other paramyxoviruses, 
the P gene contains a putative editing site for the production of V and W proteins 
(Subbiah et al., 2008).  
The F protein of paramyxovirus is synthesized as an inactive precursor (F0) 
and is cleaved to two biologically active disulfide bonded F1–F2 subunits by host 
proteases (Lamb and Parks, 2007). The cleavage of F protein is necessary for virus 
entry and cell to cell fusion. The F protein cleavage site is a well-characterized 
determinant of NDV pathogenicity in chickens. Virulent NDV strains typically 
contain a polybasic cleavage site that contains the preferred recognition site for furin 
(R-X-K/R-R↓), which is an intracellular protease that is present in most cells. This 
provides for efficient cleavage in a wide range of tissues, making it possible for 
virulent strains to spread systemically. In contrast, avirulent NDV strains typically 
have basic residues at the −1 and −4 positions relative to the cleavage site and depend 
on secretory protease (or, in cell culture, added trypsin) for cleavage. This limits the 
replication of avirulent strains to the respiratory and enteric tracts where the secretory 









identical to the pattern of avirulent NDV strains. Conversely, the F1 subunit of strain 
Yucaipa begins with a phenylalanine residue, as is characteristic of virulent NDV 
strains, rather than a leucine residue, as seen in most avirulent NDV strains (Collins et 
al., 1993). We found that strain Yucaipa replicated in a wide range of cells without 
the addition of exogenous protease, and the inclusion of protease did not improve the 
efficiency of replication (Subbiah et al., 2008). Interestingly, APMV-2 produces 
single cell infections and does not cause syncytia, a hallmark of paramyxovirus 
cytopathic effect (CPE). This is incongruent with the observation that the F protein 
cleavage site is not polybasic and does not conform to the preferred furin motif. Thus, 
strain Yucaipa is an example of paramyxovirus in which efficient intracellular 
cleavage occurs in the absence of an apparent furin motif. 
To study the effect of mutations at the F protein cleavage site on virulence and 
pathogenesis, we have developed a reverse genetics system for APMV-2 strain 
Yucaipa. Infectious APMV-2 was produced for the first time by coexpression of a 
complete cDNA-encoded antigenomic RNA in the presence of the N, P and L 
proteins. The full-length APMV-2 cDNA clone was used to generate twelve APMV-2 
mutants whose F protein cleavage site resembled those of APMV-1 through -9. Here, 
we show that all F protein cleavage site mutants were viable and that the mutations 
were maintained after virus propagation in embryonated chicken eggs. The virulence 
and pathogenicity of the mutant viruses were evaluated by mean death time in 9-day-
old embryonated chicken eggs, by intracerebral pathogenicity test in 1-day-old chicks 
and by natural route of infection of 2-week-old chickens. Our results showed that the 




in cell culture, but did not change the virulence and pathogenicity of the viruses in 
chickens. These results suggest that the cleavability of F protein is not a determinant 
for virulence of APMV-2.  
 
6.4 Materials and Methods 
 
6.4.1 Virus and Cell lines. APMV-2 strain Yucaipa (APMV-2/Yuc) was obtained 
from the National Veterinary Services Laboratory, Ames, Iowa. The virus was grown 
in allantoic cavity of 9-day-old embryonated, specific pathogen-free (SPF) chicken 
eggs. The allantoic fluid was collected on 3 day post inoculation (dpi) and 
hemagglutination (HA) titers were determined using 0.5% chicken RBC at room 
temperature. DF1 (Chicken embryo fibroblast cell line), HEp-2 (Human Epidermoid 
carcinoma tissue from the larynx) and MDCK (Madin Darby Canine Kidney) were 
maintained in DMEM with 5% fetal bovine serum (FBS). Vero cells (African green 
monkey kidney cell line) were maintained in EMEM with 5% FBS. In experiments 
that required supplementation of exogenous proteases for cleavage of the F protein, 
either 1ug/ml of trypsin or 5% allantoic fluid was used. The ability of the viruses to 
produce plaques was tested in DF1, Vero and MDCK cell lines under 0.8% methyl 
cellulose overlay. Plaques were visualized by staining with 1% crystal violet or by 
immunoperoxidase method using polyclonal antiserum. 
 
6.4.2 Construction of expression plasmids and full length cDNA clones. For 




(ORF) of N (nt 141- 1514) and P (nt 1681-2880) genes were cloned into expression 
vector pGEM7Z under T7 promoter between SphI and HindIII, EcoRI and SacI 
enzyme sites, respectively.  The ORF of L (nt 7938-14666) gene was subcloned as 
two fragments into pTM1 vector under T7 promoter using enzyme sites NcoI, StuI 
and SacI. The site SacI was artificially created by G11468C mutation within the L 
ORF without changing any amino acids. The N, P and L expression plasmids (pN, pP 
and pL) were used as the support plasmids for the recovery of the recombinant 
viruses. The full length cDNA of APMV-2 was cloned into vector pBR322/dr/Yuc, a 
plasmid generated by cloning a 73-nt oligonucleotide linker sequence containing 
unique restriction enzymes between AscI and RsrII sites in the pBR322/dr plasmid. 
The plasmid pBR322/dr is the modified form of plasmid pBR322, designed to include 
a 72-nt oligonucleotide linker between the EcoRI and PstI sites, an 84-nt hepatitis 
delta virus (HDV) antigenome ribozyme sequence and a T7 RNA polymerase 
transcription termination signal (Krishnamurthy et al., 2000). The full length cDNA 
clone (pAPMV-2) encoding the complete 14,904 nt long anti-genome of APMV-
2/Yuc was divided into six fragments and sequentially cloned into pBR322/dr/Yuc 
plasmid between the T7 promoter and HDV antigenome ribozyme sequence. A total 
of five unique restriction enzyme sites were created in the full length cDNA by 
mutating 10 nt without changing any amino acids, as described in the previous 
chapter. The third segment containing the F ORF was flanked by NotI and PacI 
enzyme sites. The full length cDNA clones of the F protein cleavage site mutants 
were generated by replacing this fragment with a fragment containing the mutated F 




APMV-2 F protein cleavage site (KPASRF) was replaced with those of the other 
APMV serotypes 1 through 9 and also one construct, pAPMV-2 (F-L) was created 
with a leucine residue replacing the phenylalanine residue at the N terminal end of F1 
subunit. The mutated fragments were digested with NotI and PacI enzymes and were 
used to replace the third segment of pAPMV-2. The following twelve constructs were 
made; pAPMV-2, the recombinant parental clone of the wild type APMV-2/Yuc, 
pAPMV-2 (F-L) and pAPMV-2 (Type 1 v), pAPMV-2 (Type 1 av), pAPMV-2 (Type 
1 African), pAPMV-2 (Type 3), pAPMV-2 (Type 4), pAPMV-2 (Type 5), pAPMV-2 
(Type 6), pAPMV-2 (Type 7), pAPMV-2 (Type 8) and pAPMV-2 (Type 9) with the 
F protein cleavage site of APMV-1 virulent strains, APMV-1 avirulent strains, 
APMV-1 African strain (that contains five basic amino acids at the F protein cleavage 
site),  APMV-3, APMV-4, APMV-5, APMV-6,  APMV-7, APMV-8 and APMV-9, 
respectively. The full length clones of all the fusion protein cleavage site mutants 
were sequenced to their entirety using ABI 3130xl genetic analyzer (Applied 
Biosystems).  
 
6.4.3 Recovery of recombinant viruses. A recombinant vaccinia virus expressing T7 
polymerase-based transfection system was used to recover infectious recombinant 
APMV-2 from the constructed cDNAs (He et al., 1997; Leyrer et al., 1998; 
Krishnamurthy et al., 2000). The transfection of full length cDNA clone along with 
support plasmids was performed in HEp-2 cell monolayer in 6-well plates. Briefly, 
the HEp-2 cells were grown to monolayer in DMEM at 37
0
C and 5% C02. When the 




transfection. The HEp-2 monolayer was transfected with 5 µg of respective full 
length cDNA plasmids and 3, 2 and 1 µg of pN, pP and pL, respectively in 100 µl of 
opti MEM per well. Along with the transfection mixture, 1 focus-forming unit per 
cell of recombinant vaccinia virus (MVA/T7) expressing T7 RNA polymerase was 
added in a volume of 0.8 ml Opti-MEM/well. Transfection was completed using 
Lipofectamine 2000 (Invitrogen, USA) according to manufacturer‟s instructions. The 
transfection mixture was replaced after 6 h with 1% DMEM. Two days after 
transfection, the HEp-2 cells were „frozen and thawed‟ three times and the resulting 
supernatant was inoculated into the allantoic cavities of 9-day-old embryonated SPF 
chicken eggs. The allantoic fluid was harvested 3 dpi and tested for HA activity. 
Allantoic fluid with a positive HA titer were used for the isolation of the viral RNA 
genome followed by sequence analysis of the third fragment that included the F 
protein cleavage site and one of the unique restriction sites (such as PmeI site 
between P and M gene) that served as a genetic marker in the recombinant viruses. 
The recovered F protein cleavage site mutants were passaged three times in 9-day-old 
embryonated SPF chicken eggs and their stability was verified by sequencing the F 
protein cleavage site in each passage.  
 
6.4.4 Growth characteristics of F protein cleavage site mutant viruses. The 
growth characteristics of the parental and mutant viruses were evaluated in DF1, Vero 
and MDCK cells with and without 5% allantoic fluid supplementation in the medium. 
The cells were observed daily for cytopathic effects (CPE) and HA titers were 




The growth kinetics of the parental and mutant viruses in comparison with the 
wild type virus was performed in DF1 cells. Briefly, DF1 cells grown in six-well 
plates were infected with the viruses at an MOI of 1 with or without exogenous 
protease supplementation. After 1 h adsorption, the infected cells were washed with 
PBS, the medium was replaced and the cultures were incubated at 37
⁰
C in an 
incubator. At 24, 48, 72, 96, and 120 h post-infection 200 µl of culture supernatants 
were collected and stored at -70
⁰
C for virus titration. Virus titers of the samples were 
determined by serial end-point assay on DF1 cells in 96-well plates. The infected 
cells were stained by immunoperoxidase method using the polyclonal antiserum 
raised against APMV-2/Yuc in chickens. The virus titers (TCID50/ml) were calculated 
using Reed & Muench method (Reed & Muench, 1938).  
The ability of the mutant viruses to produce plaques was tested in DF1, Vero 
and MDCK cells under 0.8% methylcellulose overlay with and without exogenous 
supplementation of 5% allantoic fluid. The plaques were stained by 1% crystal violet 
or immunostained using polyclonal antiserum raised against APMV-2/Yuc in 
chickens, in DF1 and Vero cells on 3 dpi or in MDCK cells on 7 dpi depending on the 
onset of plaques. 
 
6.4.5 Pathogenicity tests. The virulence of the parental and mutant viruses was 
determined by two standard pathogenicity assays: mean death time (MDT) in 9-day-
old embryonated SPF chicken eggs and intracerebral pathogenicity index (ICPI) test 









each diluent was inoculated into the allantoic cavities of five 9-day-old SPF 
embryonated chicken eggs (BEE eggs company, PA) and the eggs were incubated at 
37
o
C. The eggs were candled 3 times a day for the next 7 days, and the time of 
embryo death if any were recorded. The minimum lethal dose (MLD) is the highest 
virus dilution that kills all the embryos. The MDT is the mean time in hours for the 
MLD to kill all the inoculated embryos. The MDT has been used to classify APMV-1 
strains into the following groups: velogenic strains (taking less than 60 h to kill); 
mesogenic strains (taking 60 -90 h to kill); and lentogenic strains (taking more than 
90 h to kill). 
For ICPI, 0.05 ml (1:10 dilution) of fresh infective allantoic fluid of each virus 
was inoculated into groups of ten 1-day-old SPF chicks via the intracerebral route. 
The inoculation was done using a 27-gauge needle attached to a 1 ml stepper syringe 
dispenser that was set to dispense 0.05 ml of inoculum per bird. The birds were 
inoculated by inserting the needle up to the hub into the right or left rear quadrant of 
the cranium. The birds were observed for clinical symptoms and mortality, once 
every 8 h for a period of 10 days. At each observation, the birds were scored: 0 if 
normal, 1 if sick and 2 if dead. ICPI is the mean score per bird per observation over 
the 10-day period. Highly virulent, velogenic viruses give values approaching 2, and 
avirulent or the lentogenic viruses give values close to 0. 
 
6.4.6 Effect of the number of basic amino acids at F protein cleavage site of 
mutant viruses on the pathogenesis in 2-week-old chickens. The effect of the 




pathogenesis and tissue tropism was determined by experimentally infecting 2-week-
old SPF chickens with mutant viruses that  differed from one another by the number 
of basic amino acids at the their F protein cleavage site: rAPMV-2 (Type 4), rAPMV-
2, rAPMV-2 (Type 3), rAPMV-2 (Type 1 v) and rAPMV-2 (Type 5) with one, two, 
three, four and five basic amino acids at their F protein cleavage site were chosen. 
Briefly, groups of six 2-week-old SPF chickens were inoculated with 0.2 ml of 2
8
 HA 
units of viruses by oculonasal and intra tracheal route. The birds were observed daily 
and scored for any clinical signs for 7 dpi. Three birds from each group were 
euthanized on 3 and 7 dpi and oral and cloacal swabs were taken. The following 
tissues were collected on 3 dpi on dry ice for virus isolation and 
immunohistochemistry: brain, trachea, lungs, spleen, kidney and caecal tonsils. On 7 
dpi, only brain, trachea and lungs were collected for virus isolation.  
 
6.4.7 Virus isolation from swabs and titration of tissue sample. The oral and 
cloacal swabs were collected in 1 ml of PBS containing antibiotics (2000 unit/ml 
penicillin G, 200 µg/ml of gentamicin sulfate and 4 µg/ml of amphotericin B; Sigma 
Chemical Co., St. Louis, MO). The swab containing tubes were centrifuged at 1000x 
g for 20 min, and the supernatant was removed for virus isolation. Virus isolation was 
performed by inoculating the supernatant into the allantoic cavity of 9-day-old SPF 
embryonated chicken eggs and after 3 dpi the allantoic fluid was tested for HA 
activity. The HA-positive samples were further confirmed by HI tests with APMV-2 
specific antiserum. The virus titers in the tissue samples were determined by the 




was serially diluted and used to infect DF1 cells.  The 50% end-point tissue culture 
infectious dose (TCID50/ml) was then calculated using Reed & Muench method after 
immunostaining the virus infected cells  on 4 dpi (Reed & Muench, 1938).  
 
6.4.8 Immunohistochemistry and Histopathology. The frozen tissue samples 
collected on 3 dpi were sectioned at Histoserve, Inc. (Germantown, Maryland, USA). 
Briefly, the frozen sections were rehydrated in three 10-min changes of PBS. The 
sections were fixed in ice cold acetone for 15 minutes at -80
o
C and then washed three 
times and blocked with 2% BSA for 1 h at room temperature inside a humidified 
chamber. The sections were incubated with a 1:500 dilution of the primary polyclonal 
antiserum for 2 h at RT. After three washes with PBS, the sections were incubated 
further with the HRP conjugated goat anti-chicken secondary antibody for 30 min. 
After a final wash cycle, the sections were incubated with DAB (Vector laboratories, 
USA) for two minutes, washed with distilled water and counterstained with 
hematoxylin (Vector laboratories, USA). Sections were mounted with mounting 
medium and examined under light microscope and microphotographs were taken 
(Zeiss Axiovert 200M). For histopathology, tissue samples were collected from the 
brain, trachea, lung, spleen, caecal tonsils and kidney collected on 3 dpi were fixed in 
10% neutral buffered formalin. The fixed tissues were processed, embedded with 









6.5.1 Construction of full length APMV-2 cDNA clones. The cDNA clone 
encoding the antigenome of APMV-2 strain Yucaipa was constructed from six cDNA 
segments that were synthesized by RT-PCR from virion-derived genomic RNA (as 
described in chapter 5). The cDNA segments were cloned in a sequential manner into 
a low copy number plasmid pBR322/dr/Yuc between T7 promoter and hepatitis delta 
virus ribozyme sequence. The resulting APMV-2/Yuc cDNA in the plasmid 
pBR322/dr/Yuc was a faithful copy of the APMV-2/Yuc genome, except for the 
following nucleotide changes from the published sequence (Subbiah et al., 2008) that 
were made to create unique restriction enzyme sites without causing any amino acid 
changes, necessary to facilitate assembly and to serve as genetic marker: C2923A, 
G2924A, T2925A, G2926C, G4154C, G5971A, A5973T, T7870C, A11321G and 
A11322C. The construct contains a T7 promoter which initiates a transcript with 
three extra G residues at its 5‟ end. It has been shown in other paramyxoviruses that 
the presence of extra G residues do not prohibit the rescue of infectious virus from 
cDNA (Krishnamurthy et al., 2000).  
 To generate APMV-2 antigenomic cDNAs with mutations in the F protein 
cleavage site, the third segment (between 4193 to 5976 nt in the genome) that 
contained the F protein cleavage site was removed using NotI and PacI sites. 
Mutations of the F protein cleavage site were performed by overlapping PCR. The 
resulting cDNA fragments were then used to replace the third cDNA segment in the 





6.5.2 Recovery of infectious parental and F protein cleavage site mutant viruses. 
The strategy for producing infectious APMV-2 from cDNA-encoded antigenomic 
RNA has been described previously for other paramyxoviruses (Krishnamurthy et al., 
2000). It involved the coexpression of HEp-2 cells of the four cDNAs encoding the 
antigenomic RNA and N, P and L proteins, which are necessary for viral RNA 
replication and transcription. The cDNA transcription was driven by T7 RNA 
polymerase supplied by a vaccinia –T7 recombinant virus strain MVA. The 
supernatants from the transfected HEp-2 monolayers were inoculated into the 
allantoic cavities of 9-day-old embryonated SPF chicken eggs. The allantoic fluid 
harvested 3 dpi was tested for HA activity. Allantoic fluid with a positive HA titer 
was used for the isolation of the viral RNA genome followed by sequence analysis of 
RT-PCR of segment number three that contained the F protein cleavage site. The 
results indicated that the parental and the F protein cleavage site mutants could be 
recovered from full-length cDNA clones. None of these recombinant viruses required 
the addition of exogenous protease during transfection and recovery. Each of these 
viruses (Table 6.1) was passaged three times in 9-day-old embryonated SPF chicken 
eggs and the nucleotide sequence of the F protein cleavage site was determined. The 
sequence data showed that all the mutations introduced in the F protein cleavage site 








Table 6.1. The fusion (F) protein cleavage sites of different APMV serotypes that 
were incorporated into the F protein cleavage site of APMV-2.   
The segment III in pAPMV-2/Yuc was mutated by overlap PCR to change the F 
protein cleavage site, digested using NotI and PacI sites and subcloned into the full 
length cDNA to generate rAPMV-2 F protein cleavage site mutants.  The basic amino 
acids (K and R) at the F protein cleavage site are shown in bold.  The arrow indicates 
site of cleavage. 
 
6.5.3 Growth characterization of parental and F protein cleavage site mutant 
viruses in cell culture. All the twelve recombinant viruses replicated in DF1, Vero 
and MDCK cells without requiring the supplementation of exogenous proteases. In 
general all the viruses replicated well in DF1 and Vero cells, while their growth 
pattern was comparatively slower in MDCK cells. The parental recombinant virus, 
rAPMV-2, resembled the wild type virus in its growth characteristics, causing single-




viruses except rAPMV-2 (F-L) produced syncytia and plaques under methyl cellulose 
overlay in the DF1 and Vero cells by 3 dpi and in MDCK cells by 7 dpi (Fig. 6.1). 
There was no significant difference in the morphology and size of the plaques 
produced by the F protein cleavage site mutants. The mutant virus, rAPMV-2 (F-L), 
produced single-cell infections in all the three cell lines, similar to the CPE of wild 






Fig. 6.1 Plaque formation in DF1, Vero and MDCK cell lines on 3, 3 and 7 days post 
infection, respectively, under methyl cellulose overlay in the absence of exogenous 
protease supplementation.  
The plaques were visualized by immunoperoxidase staining using polyclonal sera 
raised against APMV-2 strain Yucaipa in chicken. 
   
The efficiency of replication in tissue culture of the parental and F protein 
cleavage site mutant viruses was compared in a multi-step growth cycle. The 
monolayers of DF1 cells were infected with the viruses and samples were collected at 
24 h intervals and quantitated by TCID50 method. This analysis showed that all the 
syncytia forming mutant viruses grew to 10-fold higher titer compared to the wild 
type, rAPMV-2 and rAPMV-2 (F-L) (Fig. 6.2). The kinetics and magnitude of 









Fig. 6.2 Comparison of kinetics of replication between wild type and fusion 
cleavage site mutants of APMV-2 in DF1 cells. 
DF1 cells in six-well plates were infected in triplicates with wt and 
recombinant viruses at an MOI of 1 and samples were taken from the culture 
supernatant at 24 h interval until 120 h post-infection. Virus titers of the samples were 
determined by serial end-point dilution in 96-well plates seeded with DF1 cells and 
immunoperoxidase staining using polyclonal antibody against APMV-2 strain 
Yucaipa raised in chickens. Virus titres (TCID50/ml) were calculated by using Reed & 
Muench method (Reed & Muench, 1938).  
 
6.5.4 The effect of the F protein cleavage site mutations on virulence. The 
virulence of the F protein cleavage site mutants was determined by two standard 
pathogenicity tests namely; mean death time (MDT) in 9-day-old embryonated SPF 
chicken eggs and intracerebral pathogenicity index (ICPI) in 1-day-old SPF chicks. 




MDT of the parental and F protein cleavage site mutant viruses was more than 168 h. 
However, it was observed that the mutant viruses, except for rAPMV-2 and rAPMV-




) between days 7 and 10, 
which could be due to the rapid rate of replication compared to that of wild type virus 
in embryonated chicken eggs. All the recombinant viruses had ICPI values of zero 
resembling wild type APMV-2/Yuc and APMV-1 avirulent strains. Both these tests 
suggested that the cleavability of the F protein does not influence the pathogenicity of 
APMV-2 in chickens.  
 
6.5.5 The effect of the number of basic amino acids at F protein cleavage site and 
pathogenesis in two-week-old chickens. The effect of the number of basic amino 
acids at the F protein cleavage site on the viral pathogenesis, was studied by 
experimentally infecting 2-week-old SPF chickens with recombinant viruses that 
varied from one another in the number of basic amino acids at their F protein 
cleavage site; rAPMV-2 (Type 4) with one, rAPMV-2 with two, rAPMV-2 (Type 3) 
with three, rAPMV-2 (Type 1 v) with four and rAPMV-2 (Type 5) with five basic 
amino acid residues at their F protein cleavage site were chosen for this study. The 
birds were infected with 0.2 ml of 2
8
 HA units of infective fresh allantoic fluid by 
oculonasal and intra tracheal route. The birds were observed daily for 7 dpi. There 
were no apparent clinical signs of illnesses throughout the study period in any of the 
infected groups. Histopathological examinations of tissue samples collected on 3 dpi 
revealed similar microscopic findings in all the tested recombinant viruses; the 




regeneration (Fig. 6.3a), in the lungs, mild to moderate multifocal lymphohistiocytic, 
perivascular and interstitial pneumonia was observed (Fig. 6.3b) and in the spleen, 









Fig. 6.3 Histopathological features of rAPMV-2 infected chicken.  HE stain (A, B and 
C). The lower panel shows controls of trachea, lung and spleen of uninfected chicken. 
2A: In the trachea, minimal to mild attenuation and flattening of the tracheal 
epithelium with reduction and loss of cilia was observed.  There was loss of normal 
columnar epithelial architecture in these regions with mild epithelial hyperplasia and 
multifocal replacement by low cuboidal epithelial cells.  Low numbers of individually 
apoptotic cells were seen within the epithelium in these regions.  There was mild, 




lamina propria. In summary, minimal to mild, multifocal, lymphocytic tracheitis with 
epithelial attenuation and regeneration was noted. 2B: In the lungs, small to moderate 
numbers of lymphocytes and fewer macrophages were seen infiltrating around blood 
vessels and within the interstitium.  Inflammatory cells formed dense perivascular 
aggregates that extend into the interstitium, with small numbers of inflammatory cells 
multifocally infiltrating into the lamina propria subjacent to the airway epithelium.  
Small numbers of individually apoptotic cells were present in inflammatory 
aggregates. Mild to moderate, multifocal, lymphohistiocytic, perivascular and 
interstitial pneumonia was observed. 2C: In spleen, the periarteriolar sheaths and 
white pulp regions exhibited minimally reduced numbers of lymphocytes. There was 
also minimal lymphoid depletion.  
 
On 3 dpi comparison of replication of the F protein cleavage site mutant 
viruses with that of parental rAPMV-2 revealed the following; rAPMV-2 (Type 4) 
with single basic amino acid at the F protein cleavage site, had comparatively reduced 
virus titer in brain (by 6 log), in lungs, trachea and spleen (by 5 log), and in kidney 
(by 3 log) but no significant difference in titer in caecal tonsil. The replication of 
rAPMV-2 (Type 3) with three unpaired basic amino acids at the FCS, had reduced 
virus titer in brain (by 3 log) while the virus titer was increased by one log in trachea 
and spleen and by 0.5 log in lungs and kidney while no significant difference in titer 
in caecal tonsil. The replication of rAPMV-2 (Type 1 V) and rAPMV-2 (Type 5) 
mutants each with paired basic amino acids (four and five basic amino acids, 




compared to rAPMV-2 in brain and lungs. The rAPMV-2 (Type 1 V) had reduced 
virus titer in trachea, spleen and kidney by 1.5, 6 and 6 log, respectively, but no 
significant difference in caecal tonsil. The rAPMV-2 (Type 5) had increased virus 
titer in trachea by one log, no significant difference in spleen and kidney while the 









Fig. 6.4a Replication of F protein cleavage site recombinant viruses in 
different organs of 2-week-old SPF chickens, three days post infection (dpi).  Six 
chickens in five groups were inoculated with 0.2 ml of 2
8
 HAU of rAPMV-2, 
rAPMV-2 (Type 4), rAPMV-2 (Type 3), rAPMV-2 (Type 1 v) and rAPMV-2 (Type 
5) by oculonasal and intratracheal route. Three chickens were sacrificed on 3 dpi. The 
virus titers in brain, lung, trachea, spleen, kidney and caecal tonsil are expressed in 
log 10 TCID50/g of tissue.  
On 7 dpi, rAPMV-2 (Type 3) could not be detected in brain tissue of any of 
the infected birds while the viruses with paired basic amino acids, rAPMV-2 (Type 5) 




(Type 4) and rAPMV-2/Yuc. In upper respiratory tract (trachea), the virus titer of 
rAPMV-2 (Type 3), rAPMV-2 (Type 1 v), rAPMV-2 (Type 5) and rAPMV-2 (Type 
4) were 0.5, 1, 1.5 and 2.5 log, respectively, lesser than the titer of the parental 
recombinant virus. In lower respiratory tract (lungs), rAPMV-2 (Type 1 v), rAPMV-2 
(Type 5) and rAPMV-2 (Type 4) virus titers were less by 0.5, 1 and 1.5 log, 










Fig. 6.4b Replication of F protein cleavage site recombinant viruses in 
different organs of 2-week-old SPF chickens, 7 days post infection (dpi).  Six 
chickens in five groups were inoculated with 0.2 ml of 2
8
 HAU of rAPMV-2, 
rAPMV-2 (Type 4), rAPMV-2 (Type 3), rAPMV-2 (Type 1 v) and rAPMV-2 (Type 
5) by oculonasal and intratracheal route. Three chickens were sacrificed on 7 dpi. The 
virus titers in brain, lung, and trachea are expressed in log 10 TCID50/g of tissue.  
Viral antigens were detected by immunohistochemistry in tissue samples that 




showed the presence of large amount of viral antigens in epithelial linings (Fig. 6.5). 
All the infected birds were seropositive by 7 dpi as observed by HI test. There was no 
significant difference in oral or cloacal viral shedding between the parental and F 
protein cleavage site mutant viruses either on 3 or 7 dpi.  
 
Fig. 6.5 Immunohistochemistry with DAB staining of tissues samples collected three 
days post infection with rAPMV-2/Yuc. Hematoxylin counterstain. 
a. Infected chicken brain, b. Infected chicken kidney, c. Infected chicken spleen, d. 
Infected chicken caecal tonsil, e. Infected chicken trachea, f. Infected chicken lung.  
 
6.6 Discussion 
In paramyxoviruses, proteolytic processing of F proteins is needed for the 
generation of mature and infectious viruses. The F protein of APMV-2 is a type I 
viral glycoprotein and shares features common to other paramyxovirus F proteins 




downstream of cleavage site, five potential N-linked glycosylation sites, a 
transmembrane domain and a cytoplasmic tail (Fig. 6.6). However, APMV-2 is 
unique with two basic amino acid residues at F protein cleavage site it does not 
require exogenous protease supplementation for growth in cell culture. Furthermore, 
APMV-2 causes single cell infections without forming syncytia.  
 
 
Fig. 6.6 Schematic representation of APMV-2 Fusion protein (F).  
The F protein is proteolytically processed into two fragments, F1 and F2, which are 
disulfide linked. Potential sites of N-linked glycosylation are indicated. The amino 
acid sequence upstream of the cleavage site is shown along with FP, fusion peptide; 
HRA and HRB, heptad repeats A and B; TM, transmembrane domain; CT, 
cytoplasmic tail.  
* HR prediction by LearnCoil-VMF program, TM –DAS TM prediction server.  
 
There are nine serotypes of avian paramyxoviruses within the genus 
Avulavirus in the family Paramyxoviridae and each serotype posses a unique F 
protein cleavage site. In APMV-1 virulent strains have multi basic cleavage site 
which are recognized and cleaved by furin, a ubiquitous cellular protease. These 




avirulent strains of APMV-1 have one or occasionally two unpaired basic amino acids 
that are cleaved by trypsin like exogenous proteases. Hence, these viruses are 
restricted to areas like respiratory and gastrointestinal tracts and they require 
supplementation of exogenous proteases for their in vitro growth. The F protein 
cleavage site of other APMV serotypes (2-9) does not seem to follow this general rule 
applicable to APMV-1.  
The F protein cleavage site of APMV-4 (DIQPR↓F) and APMV-7 (LPSSR↓F) 
contains a single basic amino acid residue, APMV-2 (KPASR↓F) has two unpaired 
basic amino acids and all these three viruses do not require exogenous protease 
supplementation for their in vitro growth in cell culture (Nayak et al., 2008; Xiao et 
al., 2009 and Subbiah et al., 2008). It is notable that all three viruses have 
phenylalanine at their F1 terminal end. APMV-5 strain Kunitachi (KRKKR↓F) does 
not require exogenous protease supplementation for in vitro growth (Samuel et al., 
2010). The requirement of exogenous protease supplementation for APMV-6 
(APEPR↓L) varies with strains. The other APMV serotypes, APMV-3 (RPRGR↓L), 
APMV-8 (YPQTR↓L), and APMV-9 (IREGR↓I) require exogenous protease 
supplementation for in vitro growth. It is interesting to note that these three serotypes 
have a leucine or isoleucine as the first amino acid at the N terminal end of F1 
subunit.  Each of these APMV serotypes have been isolated from different avian 
species and are host specific, for example, APMV-2 is endemic among passerines and 
causes severe respiratory illness in parrots, but only mild respiratory illness in 




chickens. Hence their behavior could also be contributed in part by the environment 
provided within their natural host. 
The F protein cleavage is required for activating the virus infectivity, and the 
distribution of activating proteases in the host is a major determinant of tissue tropism 
and, as such, the pathogenicity (Rott et al., 1995). Furthermore, the F protein 
cleavage site has been shown to determine the viral pathogenicity in NDV (Peeters et 
al., 1999; Panda et al., 2004). The World Organization for Animal Health or Office 
International des Epizooties (OIE) states that “virulent NDV can be defined by the 
presence of multiple basic amino acids at the C-terminus of the F2 protein and 
phenylalanine at residue 117, the N-terminus of the F1 protein”. There are some 
exceptions to this general rule; three isolates from china; SQZ/04, JS05/03, and 
QE01/99 have lentogenic F protein cleavage site motif (GRQGR↓L) but still are 
virulent in chickens (Tan et al., 2008). The pigeon paramyxovirus (PPMV-1), an 
NDV variant has virulent NDV F protein cleavage site motif and yet it is avirulent in 
chickens.  
In this current study we examined the role of amino acid sequence at the F 
protein cleavage site in the APMV-2 virulence and pathogenesis. In order to 
determine the molecular basis for APMV-2 virulence, we have developed a reverse 
genetics system for recovery of infectious recombinant APMV-2 from cloned cDNA 
for the first time. In this system, recombinant vaccinia virus expressing T7 RNA 
polymerase was used to synthesize the antigenomic RNA from the full-length cDNA 
clone and the proteins N, P, and L from the cotransfected expression plasmids.  We 




resembling the F protein cleavage site of a particular naturally occurring APMV 
serotype and one mutant where the phenylalanine at the N terminal end of F1 subunit 
was replaced by a leucine residue.   
We were able to recover all the above mentioned F protein cleavage site 
mutants without exogenous protease supplementation; hence it suggests that no 
adverse changes happened to affect the F protein folding. All the cleavage site 
mutations were maintained after several passage in embryonated eggs. Irrespective of 
the F protein cleavage site or the type of cell line used, none of the rAPMV-2 F 
protein cleavage site mutants required exogenous protease supplementation for in 
vitro growth in cell cultures, resembling the wild type virus. Similar to wild type 
APMV-2/Yuc, the recombinants rAPMV-2 and rAPMV-2 (F-L) caused single cell 
infections, while the other F protein cleavage site mutants produced syncytia and 
plaques in DF1, Vero and MDCK cell lines. This result suggested that these mutants 
are able to cause cell to cell fusion leading to syncytia formations. It is possible that 
the changes in aa sequence at the F protein cleavage site might have produced 
conformational changes favoring efficient cleavage of F protein, resulting in the 
syncytia formation. Our growth kinetics results showed syncytia formation increased 
the replication of the mutant viruses slightly, suggesting that syncytia formation 
probably causes efficient cell to cell spread of the virus.  
A single amino acid change at the N terminal end of F1 subunit did not cause 
any change in the growth characteristics of APMV-2. Previously, it has been shown 
in APMV-1 F protein that the phenylalanine residue at F1 amino terminal end is not 




protein cleavage (Morrison et al., 1993). But the F protein cleavage site mutant 
rAPMV-2(F-L) with a leucine residue at the N terminal end of F1 subunit was similar 
to wild type APMV-2/Yuc in in vitro growth pattern and kinetics and did not require 
exogenous protease supplementation. This mutant was also avirulent suggesting that 
the amino acid at this position does not affect the pathogenicity of APMV-2.  
The Nipah and Hendra viruses consist of mono basic amino acid at their F 
protein cleavage site (arginine and lysine, respectively), both cause fatal systemic 
infections and do not require trypsin supplementation. These viruses are cleaved by 
cellular cysteine protease, cathepsin L in endosomes unlike other paramyxoviruses 
that are either cleaved in golgi by furin or extracellularly by trypsin like proteases 
(Pager & Dutch, 2005; Diederich et al., 2005 and Pager et al., 2006).  In Nipah virus 
F protein, an introduction of multi basic sequence at F protein cleavage site does not 
allow cleavage by furin but actually prevents activation by any cellular protease. 
Hence the conformation around the cleavage sites probably determines exclusive 
activation by cathepsin L, a cysteine protease, or selective cleavage by the serine 
proteases trypsin and furin (Diederich et al., 2009). Similar phenotype has been 
observed with WSN strain of influenza A virus that has monobasic cleavage site in 
Hemagglutinin (HA) protein but does not require exogenous protease 
supplementation for plaque formation.  The type of amino acid and the position also 
influences the F protein cleavability; In Influenza virus A/turkey/Ireland/1378/85 
(H5N8), the lysine replacement of arginine at the carboxy terminal of HA1 abolished 




In F1-R, a Sendai virus mutant, replacement of serine at position -1 by a 
proline residue changed the phenotype from pneumotropic to pantropic (Tashiro et 
al., 1988). In SV5, a series of mutant F proteins produced by site directed 
mutagenesis revealed that the minimum number of arginine residues for cleavage 
activation of F protein by host cell proteases was four and those with 2 or 3 arginine 
residues were cleaved by exogenous protease supplementation and the F protein with 
a single arginine residue was not cleaved. It was also shown that the connecting 
peptide affected the local conformation of F polypeptide but not the biological 
activity (Paterson et al, 1989).  Apart from the number, position and the type of 
amino acids at the cleavage site, there are other factors that affect the cleavability and 
hence the fusion activity, such as a carbohydrate side chain in the vicinity of F protein 
cleavage site or point mutations at a distance from F protein cleavage site (Rott & 
Klenk 1988 and Orlich et al., 1990). In NDV, the interaction between the heptad 
repeat domain (HR 2) of fusion protein is found to be important for the fusion 
promotion activity through interaction between F and HN proteins (Gravel & 
Morrison, 2003).  
In our study, we found that irrespective of the amino acid sequence at the F 
protein cleavage site, the MDT of APMV-2 F protein cleavage site mutants were 
more than 168 h and ICPI values were zero similar to wild type APMV-2/Yuc, 
suggesting that the F protein cleavage site does not play a role in the virulence of 
APMV-2. In addition, the role of number of basic amino acids at the F protein 
cleavage site in pathogenesis was studied in 2-week-old chickens. We chose five 




their F protein cleavage site; rAPMV-2 (type 4), rAPMV-2, rAPMV-2 (type 3), 
rAPMV-2 (type 1 v) and rAPMV-2 (type 5) with 1, 2, 3, 4 and 5 basic amino acids, 
respectively, at the F protein cleavage site. Our results demonstrated that monobasic F 
protein cleavage site containing virus in general replicated inefficiently compared to 
the parental dibasic recombinant. Our results did not show any significant difference 
in the viral replication and tissue tropism among the F protein cleavage site, 
suggesting no direct correlation between the number of basic amino acids at F protein 
cleavage site and pathogenicity of APMV-2.  
We have shown here that the prerequisite for fusion activation in APMV-2 is 
different from other paramyxoviruses and is dependent on the amino acid sequence at 
F protein cleavage site. Our results suggest that the F protein of wild type virus is 
somehow able to initiate infection without causing cell fusion. Any change in the 
amino acid sequence at the F protein cleavage site causes a local conformational 
change which leads to cleavage of the F protein and cell to cell fusion or syncytia 
formation. The cell to cell fusion probably causes slight increase in virus replication. 
However, this cell to cell fusion does not increase the virulence or pathogenicity of 
the virus. The pathogenicity of APMV-2 is probably dependent upon other viral or 
host factors. The availability of a reverse genetics system to recover infectious 
APMV-2 from cloned cDNA will expand our understanding of not only APMV-2 but 















7.2 Conclusion and Future prospects:  
 
 
Family Paramyxoviridae includes important human pathogens such as mumps 
virus, measles virus and Nipah viruses and animal pathogens such as Newcastle 
disease virus (NDV), rinderpest virus and canine distemper virus. NDV or avian 
paramyxovirus (APMV) serotype 1 is an important poultry pathogen that causes 
severe economic loss to poultry industries around the world. There are nine different 
serotypes of APMV among which NDV is the most characterized virus and very little 
is known about the other serotypes. APMV-2 causes mild clinical illness in chickens 
and turkeys, which gets exacerbated with secondary bacterial infections. There are 
also reports of APMV-2 infection causing drop in egg production in chicken and 
turkey commercial farms. Surveillance studies have shown the endemic existence of 
APMV-2 among passerines and other wild birds across the globe. Prior to this study, 
only the epidemiological data of APMV-2 infections were available. In this study 
four strains of APMV-2 (prototype strain Yucaipa and strains Bangor, England and 
Kenya) were characterized both in vitro and in vivo. A sensitive immunoperoxidase 
method was standardized for titrating APMV-2 strains since none of the viruses 
produced plaques in cell culture.  All four APMV-2 strains were found to be avirulent 




embryonated chicken eggs and ICPI in day-old chicks.  The pathogenesis of strains 
Yucaipa and Bangor in 4-week-old chickens and turkeys was studied which 
demonstrated that neither of the strains is virulent in both species of birds and that 
strain Yucaipa replicated better in chickens than in turkeys. 
As a first step towards molecular characterization, the complete genome 
sequences of all the four APMV-2 strains were determined and compared with other 
paramyxoviruses. The genome lengths of strain Yucaipa, Bangor, England and Kenya 
were 14904, 15024, 14904 and 14916 nt, respectively. The genome sequence and 
phylogenetic analyses justified the classification of APMV-2 under the genus 
Avulavirus within the family Paramyxoviridae and also indicated the existence of two 
subgroups within serotype 2. The concept of subgrouping was further supported by 
cross HI and cross neutralization tests in cell culture between homologous and 
heterologous sera. We propose that the strains Yucaipa, England and Kenya form one 
subgroup while strain Bangor represents another subgroup.  
The availability of complete genome sequence enabled construction of a full 
length cDNA clone for APMV-2 strain Yucaipa (APMV-2/Yuc) and subsequent 
recovery of infectious recombinant virus by reverse genetics system previously 
established in our laboratory for avian metapneumo virus, bovine respiratory 
syncytial virus and NDV using a recombinant vaccinia (expressing T7 polymerase)-
based approach. The development of reverse genetics system has several downstream 
applications such as engineering of vaccines, generation of vaccine vectors and to 
study molecular biology. In this study, two infectious recombinant viruses expressing 




for five consecutive passages in DF1 cells and in chicken embryos suggesting that 
this system could be used to develop APMV-2/Yuc as a vaccine vector against 
emerging pathogens. 
Previously, it has been shown that the nature and composition of amino acids 
at the fusion (F) protein cleavage site determines the virulence of APMV-1 (Peters et 
al., 1999; Panda et al., 2004). Using reverse genetics approach, eleven APMV-2/Yuc 
recombinant viruses were recovered, each with F protein cleavage site resembling a 
particular APMV serotype, and one recombinant with leucine residue in place of 
phenylalanine at the F1 N terminal end. Our results demonstrated that mutations at 
the F protein cleavage site led to plaque formation in cell culture, but did not affect 
the pathogenicity of the virus. It was also shown that the F1 N terminal amino acid 
did not play any role in APMV-2 in vitro growth characteristics or in vivo 
pathogenicity.   
This study has opened up new ways to develop vaccines, vaccine vectors and to 
study molecular biology of paramyxoviruses. It will be interesting to study the 
following in future: (i) antigenic and sequence analyses of additional APMV-2 strains 
(ii) The molecular mechanism of cleavage of APMV-2 fusion protein (iii) application 
of APMV-2 reverse genetics system to develop vectored vaccines against emerging 
diseases of animals and humans. 
 Science is fascinating, each and every research finding moves us a step forward 
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